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Resumo 
Os ácidos gordos polinsaturados, conhecidos por PUFA (do inglês, polyunsaturated fatty 
acids), contêm duas ou mais ligações duplas de carbono e incluem os ácidos gordos essenciais, 
ómega-6 (n-6) e ómega-3 (n-3). O ómega-6 deriva do ácido linoleico (LA, 18:2n-6) e origina o 
ácido araquidónico (AA) como metabolito final. O ómega-3 deriva do ácido linolénico (ALA, 
18:3n-3) e tem como metabolitos principais o ácido eicosapentaenóico (EPA, 20:5n-3) e ácido 
docosahexaenóico (DHA, 22:6n-3), que são ácidos gordos de cadeia longa (LC-PUFA, do 
inglês, long-chain polyunsaturated fatty acids).  
Os metabolitos do n-6 e do n-3 são originados através de uma cascata de reacções de 
dessaturação, alongamento e oxidação, com enzimas específicas. O n-6 produz também alguns 
eicosanóides com propriedades pró-inflamatórias e pró-trombóticas: lipoxinas (LXs), 
prostaglandinas (PGs), thromboxanos (TXs) e leucotrienos (LTs), que são contrabalançados 
pelos eicosanóides anti-inflamatórios do n-3. 
Os PUFA são considerados ácidos gordos essenciais porque não conseguem ser sintetizados 
de novo pelo nosso organismo e precisam de ser obtidos através da dieta. As melhores fontes de 
ácidos gordos são o peixe gordo e os seus óleos, os óleos vegetais, como óleo nozes, chia, 
canola e linhaça e também óleo ou extracto de algas marinhas. Os PUFA podem também ser 
encontrados em suplementos alimentares e no leite materno.  
O rácio de ingestão n-6/n-3 é considerado um factor de promoção da saúde humana, sendo 
os níveis baixos deste rácio recomendados para se obterem os efeitos protectores destes ácidos 
gordos, nomeadamente ao nível das suas propriedades anti-inflamatórias, cardiovasculares e 
neurobiológicas. Na dieta ocidental moderna existe um consumo excessivo de n-6 relativamente 
ao n-3, o que origina uma desregulação do metabolismo normal destes ácidos gordos, onde o n-
6 compete com o n-3 pelas mesmas enzimas e leva ao aumento dos eicosanóides pró-
inflamatórias do n-6. Há, no entanto, estudos recentes que colocam em causa o papel do rácio n-
6/n-3 e reforçam a ideia do consumo de EPA e DHA em maior quantidade, ao invés de n-3 sob 
a forma de ALA. Actualmente é recomendado o consumo de 1g/ dia de n-3 PUFa, sob a forma 
de EPA+DHA, para se obterem efeitos benéficos no sistema cardiovascular. 
O consumo de óleo de peixe, rico em EPA e DHA, tem sido associado a efeitos protectores 
no sistema nervoso central, promovendo o desenvolvimento dos circuitos corticais e afectando o 
funcionamento de neurotransmissores (serotonina, adrenalina, noradrenalina e dopamina), tendo 
consequentemente um impacto positivo na progressão de patologias neurológicas do foro 
inflamatório e também comportamental, como a depressão, ansiedade, stress e perturbações de 
humor. Condições como a depressão, a ansiedade e o stress têm um impacto negativo na 
sociedade, podendo levar a situações fatais. Assim, é necessário avaliar o impacto dos ácidos 
gordos de cadeia longa na prevenção destes distúrbios.  
A maior parte dos estudos sobre EPA e DHA foca-se na toma conjunta destes ácidos gordos 
e, por isso, não clarificam o papel individual de cada um destes compostos sobre a saúde. O 
objectivo principal deste trabalho é, portanto, explorar os efeitos benéficos da toma de EPA e 
DHA, comparando a sua acção isolada com a sua acção conjunta, na promoção de 
comportamentos activos, opostos aos encontrados em situações de depressão e outros distúrbios 
comportamentais.  
Para este trabalho foram usados 32 ratos Wistar como modelo de estudo, distribuídos 
aleatoriamente por 4 dietas diferentes (com 8 animais por grupo) e ricas em ácidos gordos de 
diferentes origens, de forma a avaliar qual destes compostos tem um efeito benéfico maior sobre 
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o comportamento: óleo de peixe, rico em EPA+DHA (grupo Fish Oil), óleo de 
Nannochloropsis, uma microalga marinha rica em EPA (grupo Nanno) e óleo de 
Schizochytrium, uma alga marinha rica em DHA (grupo Schyzo). Uma dieta pobre em EPA e 
DHA (grupo Milk Fat) foi usada como controlo negativo. Os animais foram pesados duas vezes 
por semana durante dois meses, registando-se igualmente a quantidade de alimento ingerido 
nesse período.  
Para avaliar estado de actividade/passividade dos animais recorreu-se a um teste de natação 
forçada (Forced Swimming Test, FST, em inglês), em que os animais são colocados numa 
piscina com 30 cm água, num ambiente controlado e do qual não podem escapar. O teste foi 
realizado em duas fases, em dois dias consecutivos (pré-teste de 15 minutos + teste de 5 
minutos), sendo o segundo teste gravado para análise dos movimentos natatórios, frequência de 
movimentos, tempo de latência e tempo de imobilidade dos animais. O maior tempo de 
imobilidade está associado a um estado menos activo e pode ser interpretado como uma maior 
tendência para um comportamento depressivo. 
Posteriormente, os animais foram sacrificados e procedeu-se à recolha dos seus órgãos e 
sangue, usados para análise do perfil de ácidos gordos, quantificação de parâmetros bioquímicos 
e análise dos níveis de serotonina e catecolaminas. As fezes (previamente recolhidas) foram 
também analisadas para determinar o perfil de ácidos gordos e a eventual absorção destes pelo 
organismo. 
Os resultados do teste comportamental revelam um maior poder benéfico no consumo 
conjunto de EPA+DHA, uma vez que o grupo Fish Oil revelou tempos de imobilidade menores 
e uma maior latência de imobilidade. O grupo Schyzo, rico em DHA, teve valores próximos, 
embora inferiores, aos encontrados no grupo Fish Oil, tendo os grupos Milk Fat e Nanno uma 
pior prestação global no teste comportamental. 
Os resultados nas fezes revelam um maior poder de absorção para o grupo Fish Oil e menor 
para o grupo Nanno. 
A análise ao plasma revelou valores mais baixos de lípidos totais, colesterol total, 
triglicéridos e glucose para o grupo rico em EPA+DHA, bem como níveis mais altos de 
dopamina e adrenalina, associados a um maior índice de actividade e motivação. O grupo 
Nanno, rico em EPA, apresentou bons resultados nos parâmetros ligados à saúde cardiovascular, 
o que pode indicar um papel mais benéfico deste ácido gordo, relativamente à toma de DHA. 
Os eritrócitos e o cérebro apresentaram também níveis elevados de EPA e DHA para o grupo 
Fish Oil, em comparação com os níveis encontrados nos outros grupos, revelando uma maior 
incorporação de ácidos gordos por parte da dieta rica em óleo de peixe. 
Pode concluir-se que a toma conjunta de EPA+DHA é mais benéfica para a saúde 
cardiovascular geral e para melhorar os níveis de actividade nos indivíduos do que a toma 
isolada destes compostos, uma vez que o grupo alimentado com EPA+DHA apresentou 
melhores resultados em todos os parâmetros analisados, comparativamente aos que apenas 
tomavam EPA ou DHA. 
 
Palavras-chave: Ácido eicosapentaenóico (EPA), ácido docosahexaenóico (DHA), efeitos 
neurobiológicos, Forced Swimming Test, óleo de peixe. 
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Abstract 
Polyunsaturated fatty acids include the essential omega-6 (n-6) and omega-3 (n-3) fatty 
acids, which are not synthesised by our body and must be obtained through diet. The most 
abundant sources of PUFA are fish, plant and algae oils. Omega-3 has an important anti-
inflammatory power and is known for its benefit effect on the prevention of cardiovascular 
diseases. The main n-3 metabolites are eicosapentaenoic acid (EPA, 20:5n-3) and 
docosahexaenoic acid (DHA, 22:6,n-3), the long-chain PUFA (LC-PUFA), mainly found in fish 
oil and known to have a protective role regulating brain development and neurotransmitter 
functioning. Therefore, LC-PUFA are implied for the prevention of neurodegenerative and 
neurological conditions, as well as behavioural disturbances like depression and anxiety-related 
disorders. However, there is a lack of information about the individual role of these fatty acids 
on these stated conditions. 
The purpose of this work was to test and compare the effects of EPA and DHA, in form of 
isolated and combined diet, on the promotion of active behaviours, favourable in neurologic 
disorders. An experimental design was made using 32 Wistar rats, divided into 4 different diets 
to assess the specific effects of each fatty acid: Milk Fat, the negative control diet without EPA 
or DHA added; Fish Oil, the positive control diet, rich in EPA+DHA; Nanno group, rich in 
EPA; Schyzo group, rich in DHA. A behavioural Forced Swimming Test (FST) was performed 
to evaluate the active/passive state in rats. The animals were later euthanized, with their blood 
and organs removed for biochemical analysis. Fatty acid profile in faeces, erythrocytes and 
brain, as well as biochemical markers, serotonin and catecholamines levels were determined. 
Behavioural FST revealed benefit effects of the EPA+DHA intake, rather than individual 
fatty acid intake, since Fish Oil group presented a better overall performance. Both Milk Fat and 
Nanno groups presented the worse results in FST, with higher immobile levels, low latency 
times and higher frequencies. Schyzo group has more similar results to Fish Oil group than 
Nanno group, which might indicate a better role of individual DHA, contrarily to individual 
EPA, on promoting active behaviours. Plasma metabolites, as well as dopamine and epinephrine 
levels, also presented better results in Fish Oil group, with Nanno group having similar results 
as Fish Oil regarding plasma metabolites related with cardiovascular health. 
It can be concluded that an EPA+DHA diet is more adequate for the promotion of global 
health, as well as increasing active behaviours, which can be benefit for neurologic conditions. 
 
Key words: Eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), fish oil, Forced 
Swimming Test, neurobiological effects. 
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Introduction 
Neurologic disorders are a major concern of modern times as they are growing, mainly due to an 
increase in the average life expectancy (Klenk et al., 2016), sedentarization (van Alphen et al., 2016), 
poor lifestyle choices, diet and lack of physical health (Jelinek et al., 2013; van Reedt Dortland et al, 
2013), maternal malnutrition (Morgese and Trabace, 2016), social environment and other socio-
economic factors (Das et al., 2015; Payne et al., 2014; Hofmann and Asnaani, 2010). Diet seems to be 
a key factor on the development of mental disorders since central nervous system (CNS) is highly 
enriched in fatty acids, particularly long-chain polyunsaturated fatty acids (LC-PUFA), which are 
essential in foetal and neonatal brain development (Crupi et al., 2013).   
Omega-3 fatty acids are pointed as the most beneficial fatty acids in retarding neurologic disorders, 
which include Alzheimer, Parkinson’s and Huntington’s disease, multiple sclerosis, schizophrenia, 
cognitive decline and brain ageing, major depression, acute stress and anxiety like behaviours (Cutuli 
et al., 2014; Molfino et al., 2014; Dyall and Michael-Titus, 2008; Ferraz et al., 2011). From these 
conditions, major depression, acute stress and anxiety present more life-threatening risks and are the 
fastest growing, affecting people worldwide and of all ages (Iorfino et al., 2016; Avenevoli  et al., 
2015; Kessler and Bromet, 2013). Therefore, prevention and treatment of these disorders is a major 
concern and a priority.  
Within the n-3 PUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the 
precursors whose properties are pointed as most benefit on retarding and treating the neurologic 
conditions stated above (Bozzatello et al, 2016; Dyall, 2015), but is not clear yet if the benefits 
associated to EPA and DHA are specific of one of the precursors or come as the combination and 
interaction of both fatty acids (Song et al., 2016; Russell and Bürgin-Maunder, 2012).  
It is important to clarify the particular role of individual EPA, individual DHA and the combined 
EPA+DHA formula on the promotion of more active behaviours in rats. Hence, this thesis proposes to 
study the individual and combined effects of the LC-PUFA on rats’ behaviour. 
First, a general characterization of the most important fatty acid and their biological role will be 
presented. Second, particular effects of n-6 and n-3 will be described, included their synthesis and 
metabolic interaction. Last, the neurobiological effects of LC-PUFA will be detailed, with emphasis 
on EPA and DHA role on the promotion of active behaviours in rats and the different behavioural 
methods that can be used to evaluate the activity state.  
The protective and benefit effects of the fatty acids will be assessed by administrating three 
different diets, with fatty acids from different origins (fish oil and microalgae), in an experimental rat 
model, submitted to a behavioural stress test (Forced Swimming Test, FST) that will also evaluate the 
animals’ active/passive state. Biochemical and biological parameters associated with activity and rats’ 
normal function will also be measured. Finally, the different parameters will be analysed and 
compared in order to determine the outcome result of the different diets and which LC-PUFA form is 
more benefit for the animals’ behaviour. 
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1. Scientific background and objectives 
 
1.1.  Fatty acid general characterization 
A fatty acid (FA) is a carboxylic acid with a long unbranched aliphatic tail chain which can be 
either saturated, monounsaturated or polyunsaturated. Therefore, according to its saturated state and 
structural and functional groups present, a fatty acid can be classified as saturated fatty acid (SFA), 
monounsaturated fatty acid (MUFA) or polyunsaturated fatty acid (PUFA) (Crupi et al., 2013).  
Fatty acid in the form of triacylglycerols (TAG) are a principal source of energy (25-35% of total 
energy intake in humans) (Kremmyda et al., 2011) and are also fundamental mediators of multiple 
signalling pathways and part of the structure and function of cell membranes (Orsavova et al., 2015). 
On the other hand, some FA can be responsible for the expression of pro-inflammatory cytokines, as 
interleukins (IL) and tumour necrosis factor (TNF-α), with negative effects for the human body 
(Kremmyda et al., 2011). The potential health effect of a specific fatty acid depends both on its 
structure and administration form (Bandarra et al, 2016; Hunter, 2001). The level of saturation in a 
fatty acid gives it unique properties with distinctive functions and interactions in all living beings. The 
more saturated a fatty acid is the more benefit effects it has, being long-chain polyunsaturated fatty 
acids (LC-PUFA) considered the most benefit for lipid metabolism in humans (Grosso et al., 2014; 
Molfino et al., 2014; Dyall and Michael-Titus, 2008).  
Fatty acids can have a cis- or trans- configuration, based on the configuration of the double bonds, 
being the trans- form a result of hydrogenation process from the food industry to create more stable 
solid fats from liquid oils (Orsavova et al., 2015; Estadella et al., 2013). Trans-fats, however, are 
considered unhealthy, since they raise LDL cholesterol, lower HDL cholesterol, promote 
thrombogenesis through the eicosanoid synthesis pathway, promote insulin resistance and are 
associated with systemic inflammation and endothelial dysfunction (Hinrichsen, 2016; Imran and 
Nadeem, 2015; Qi Sun et al, 2007).  
 
1.1.1. Saturated fatty acids 
Saturated fatty acids are long-chain carboxylic acids that usually have 12 to 24 carbon atoms with 
no double bond, instead SFA are saturated with hydrogen (Crupi et al., 2013). Palmitic acid (16:0) is 
the most common saturated fatty acid and it’s usually found in palm oil, one of the most important 
edible oils globally (Hinrichsen, 2016). Other food sources for SFA include coconut oil (Orsavova et 
al., 2015), processed meat, milk, butter and other dairy products (O’Sullivan et al., 2013), salmon, egg 
yolks and chocolate (de Souza et al., 2015). 
Saturated fatty acids were commonly associated to cardiovascular diseases (CVD), dyslipidemia, 
chronic inflammation, insulin resistance (Estadella et al., 2013), obesity and morphologic alterations 
(Campos-Silva et al, 2015), atherogenic potential and increased cholesterol levels (Mensink et al., 
2003; Hunter, 2001). However, other studies questioned these adverse effects, as no clear correlation 
was found between SFA and these negative effects (Siri-Tarino et al., 2015; de Souza et al., 2015; 
O’Sullivan et al., 2013; Huth and Park 2012; Micha and Mozaffarian, 2010). 
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1.1.2. Monounsaturated fatty acids 
Monounsaturated fatty acids contain only a single double bond. An example of a common 
monounsaturated fatty acid is oleic acid (18:1n-9), that accounts for more than 92% of all MUFA 
consumed (Joris and Mensink, 2016). Oleic acid is mainly found in olive, rapeseed and sunflower oils, 
but MUFA are also generally found in red meat, whole fat milk products, nuts, avocados and canola 
oil (Lewinska et al., 2015; Orsavova et al., 2015).  
The effects of MUFA are less study than SFA and PUFA, therefore its positive role on 
cardiovascular disease (CVD) and coronary heart disease (CHD) is not very clear yet, though no 
harmful effects of MUFA-rich diets are known (Joris and Mensink, 2016). One study points out the 
beneficial effects of MUFA consumption along with fish oil, rich long-chain PUFA, on cardiovascular 
diseases, as MUFA can potentiate those benefit effects of fish oil (Kondreddy et al., 2016). Other 
studies state that oleic acid rich in MUFA appears to lower LDL cholesterol (low-density lipoprotein) 
level (Hunter, 2001) and also protected against oxidative modification of high-density lipoprotein 
cholesterol (HDL) (Lewinska et al., 2015), but those effects are considered less beneficial when 
compared to PUFA role (Joris and Mensink, 2016). 
 
1.1.3. Polyunsaturated fatty acids 
Polyunsaturated fatty acids contain two or more carbon-to-carbon double bonds in a hydrophobic 
hydrocarbon chain, not saturated with hydrogen atoms (Grosso et al., 2014). There are two main 
classes of PUFA, n-3 (formerly known as omega 3 fatty acid) and n-6 (formerly known as omega-6 
fatty acids), which differ in the position of their final carbon bond and the fatty acid from which they 
are synthesized (Crupi et al., 2013). Omega-3 and omega-6 are considered essential fatty acids (EFA) 
since they play an important role in maintaining homeostatic conditions and also because mammalian 
cells lack the desaturase enzymes required for the production of EFA, therefore these EFA must be 
obtained through diet (Grosso et al., 2014). 
The main sources of PUFA vary greatly among countries, mostly depending on food availability 
and cultural influences, but they are usually found in vegetable oils (soy, linseed, rapeseed, canola, 
walnuts, corn, sunflower, pumpkin) (Lewinska et al., 2015), fish oil (codfish, salmon, tuna, sardines), 
fish flesh and liver and also seafood and marine algae (Crupi et al., 2013; Wibrand et al., 2013). All 
PUFA are present in human breast milk, which explains why breast-fed children are healthier 
compared to bottle-fed (Das, 2003). 
 
1.2.  Biosynthesis and biological effects of PUFA 
 
1.2.1. Omega-6 PUFA 
The n-6 series derive from linoleic acid (LA, 18:2 n-6) with the double bond at the sixth carbon 
atom from the end of the carbon chain. Omega-6 PUFA can be converted into arachidonic acid (AA, 
20:4 n-6) and then metabolized into the omega-6 eicosanoids: lipoxins (LXs), prostaglandins (PGs), 
thromboxanes (TXs) and leukotrienes(LTs) (Grosso et al., 2014). 
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1.2.2. Omega-3 PUFA 
The n-3 series derived from a shorter-chained omega-3 fatty acid, α-linolenic acid (ALA, 18:3 n-3) 
with the double bond starting at the third carbon atom from the end of the carbon chain (Grosso et al., 
2014). Omega-3 synthesis forms the most important LC-PUFA metabolites: eicosapentaenoic acid 
(EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3) (Das, 2003). The health effects of omega-
3 fatty acid come mostly from EPA and DHA (Dyall, 2015; Molfino et al., 2014), which will be 
detailed further.  
The molecular structures of ALA, EPA and DHA, with their respective double bonds, are presented 
in Figure 1.1. 
 
 
Figure 1.1 Molecular structures of n-3 PUFA (ALA, EPA and DHA). Adapted from Molfino et al. (2014). 
 
 
1.2.3. PUFA synthesis 
Essential fatty acids have important effects for humans’ normal function metabolism, but their full 
benefit comes from their long-chain metabolites that can be synthesized by a series of linked 
desaturation, chain elongation and b-oxidation reactions (Calder, 2012). 
Figure 1.1 shows the conversion scheme of n-6 and n-3 to their final metabolites and the enzymes 
involved in each step. 
Omega-6 synthesis starts with the conversion of LA toγ-linolenic acid (GLA, 18:3 n-6) by the 
action of the enzyme Δ6 desaturase. Then GLA is elongated to form dihomo-GLA (DGLA, 20:3, n-6) 
and finally DGLA is converted to arachidonic acid by the action of the enzyme Δ5 desaturase (Lee et 
al., 2016). 
Omega-3 synthesis involves more steps, starting with the conversion of ALA to stearidonic acid 
(SA, 18:4 n-3) by Δ6-desaturase and SA to eicosatetraenoic acid [ETA, 20:4 n-3) by the action of 
elongase. ETA is then converted to EPA by the action of the enzyme Δ5 desaturase. EPA can be 
converted to DHA by the action of an elongase and the enzyme Δ4 desaturase, with docosapenatenoic 
acid (DPA, 22:5 n-3) being an intermediate in the pathway (Lee et al., 2016). ALA conversion to EPA 
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is referred to be generally poor and as a result, DHA conversion is considered especially limited 
(Calder, 2012). 
Both n-6 and n-3 series are metabolized by the same set of enzymes desaturases and elongases. As 
a result, conversion of ALA to EPA competes with the conversion of LA to AA, being Δ6-desaturase 
the rate limiting factor in the pathway. Delta-6 and Δ5 desaturases prefer n-3 to n-6, but their activities 
are regulated by a series of factors, such as nutritional status, hormones and end products feedback 
inhibition. For example, saturated fats, cholesterol, trans-fatty acid, protein deficiency, alcohol, 
adrenaline, glucocorticoids and fasting inhibit Δ6 and Δ5 desaturases and pyridoxine, zinc and 
magnesium are necessary co-factors for normal Δ6 desaturase activity. Insulin activates Δ6 desaturase, 
but glucose rich diets reduce it. Age also reduces the activity of Δ6 desaturase. A fat free diet and 
partial caloric restriction enhances Δ6 desaturase (Grosso et al., 2014). 
Omega-3 derived eicosanoids are less active and their anti-inflammatory action can partially 
oppose the pro-inflammatory actions of the omega-6 eicosanoids. Therefore, to prevent a deregulation 
of inflammatory processes must be a homeostatic balance between omega-3 and omega-6 fatty acid 
(Grosso et al., 2014).  
 
 
 
Figure 1.2 Biosynthesis of n-6 and n-3 fatty acids to their final metabolites. Adapted from Lee et al. (2016). 
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1.2.4. Biological effects of n-6 and n-3 
Since EPA competes with AA for enzymatic conversion, the increase of omega-6 fatty acid will 
lead to a higher production of pro-inflammatory eicosanoids that cannot be neutralized by the anti-
inflammatory effects of n-3 PUFA, which can be harmful to human body (Simopoulos, 2008). 
Lowering the ingestion of n-6 PUFA will increase de bioavailability of n-3 PUFA and, therefore, 
increase the concentration of EPA and DHA, which have benefit anti-inflammatory properties (Taha et 
al., 2014). 
During human evolution, omega-3 fatty acids were found in all foods consumed: meat, wild plants, 
eggs, fish, nuts and berries and n6/n3 ratio was ranging between 1/1 and 2/1 (Simopoulos, 2008). In 
the last 150-100 years there has been a change in human diet and lifestyle, with a crescent adoption of 
western foods and industrialized products that altered ratio of n6/n3 fatty acid consumption in many 
countries around the world (Simopoulos, 2006). Modern western diet has been estimated to have a 
15/1 to 20/1 n6/n3 ratio, which means the present diet is richer in omega-6 fatty acid in a proportion 
considered “unhealthy” for the human organism (Crupi et al., 2013). 
Some of the n-6 eicosanoids, such as prostaglandins, thromboxanes, leukotrienes, hydroxyl fatty 
acids and lipoxins, are biologically active in very small quantities and, when formed in large amounts, 
they can have a pro-inflammatory and pro-thrombotic action, which increases blood viscosity, cause 
vasospasm and vasoconstriction and decreases bleeding time (Simopoulos, 2008). Therefore, an 
increase in n-6 eicosanoids can lead to the formation of thrombus, atheromas and to allergic and 
inflammatory disorders, potentiating pathological processes and chronic conditions, such as diabetes, 
cancer, obesity, autoimmune diseases and rheumatoid arthritis (Simopoulos, 2006). Pro-thrombotic 
and pro-inflamatory eicosanoids can also lead to CVD events, elevated blood lipids and blood pressure 
levels (Khandelwal et al., 2013) and have a negative role on endothelial function, oxidative stress 
(Yang et al., 2016) and even depression disorders (Husted and Bouzinova, 2016). 
The ratio of omega-6 to omega-3 EFA is an important determinant of health, because both omega-6 
and omega-3 fatty acids influence gene expression. Since many chronic diseases begin in uterus or 
early in infancy, proper dietary intake of PUFA even prior to pregnancy may be important, as shown 
for folate deficiency in the development of neural tube defects (Simopoulos, 2006). 
Long-chain PUFA are an important constituent of the cell membranes and confer on membranes 
properties of fluidity. Thus, the ratio between omega-6 to omega-3 fatty acid is important to avoid 
imbalance of membrane fluidity (Das, 2003). The double bonds in the structure of n-3 PUFA result in 
conformations that prevent dense packing of phospholipids, thereby increasing membrane fluidity, 
which in turn affects receptor numbers and functioning, as well as serotonin neurotransmitter levels on 
the brain (Park et al., 2012). It is suggested that these changes in neurotransmitter levels may affect the 
central nervous system and modify higher brain functions (Kodas et al., 2004; Zimmer et al., 2000). 
Hence, PUFA metabolites may have an important role on neurologic diseases and behaviour 
modulation. 
However, a study from Griffin (2008) suggests that the n-6/n-3 ratio has no value as health risk. 
Instead, it can be used as a health indicator, but not determinant or prompter of disease. Griffin (2008) 
also states that the major contributors for the promotion of health are the n-3 metabolites, EPA and 
DHA, and the absolute amount of dietary PUFA are of relevance to the efficiency of the conversion of 
ALA to EPA and EPA to DHA. Therefore, a decrease in LA consumption and an increase in ALA 
consumption will promote the endogenous synthesis of LC-PUFA and increase health. 
There are some problems associated to n-6/n-3 ratio, reported by Griffin (2008): the ratio by itself 
makes no distinction between ALA and EPA and DHA metabolites; both ALA and LA have benefit 
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effect for the prevention of CVD and the ratio only counts for the final n-6 metabolites. Hence, it is 
important to evaluate the benefits of LC-PUFA regarding its amount in diet, instead of their relative 
proportion. 
Current guidelines regarding PUFA consumption recommend the intake of 1g/day of n-3, in the 
form of EPA+DHA, for secondary prevention of heart disease, treatment of post-myocardium 
infarction and prevention of sudden cardiac death and other cardiovascular dysfunctions (Russo, 
2009). 
 
 
1.3.  Neurobiological effects of LC-PUFA 
Dietary LC-PUFA have been positively associated with a variety of neurodegenerative diseases and 
neurological disorders, since PUFA are part of the membranes of neuronal cells and synapses (Dyall, 
2015), promote neurogenesis, neuroplasticity and CNS development (Tang et al., 2016; Crupi et al., 
2013) and are implied in cortical circuit maturation (McNamara et al., 2015). Also, its deficiency leads 
to impaired neuronal function, affecting neurotransmission action (Logan, 2003; Chalon et al., 1998).  
 
1.3.1. Neurotransmitters and LC-PUFA interaction 
The brain neurotransmitters, serotonin (5-HT) and catecholamines (epinephrine, EPI; 
norepinephrine, NE; dopamine, DA), are biogenic amines that transmit information between nerve 
cells or neurons and effector cells, integrating the overall coordination of human body functions (Ji et 
al., 2014). If these neurotransmitters are defected, the normal function of the nervous system is 
affected, resulting in neurologic problems, essentially at the level of emotion control, neural plasticity, 
memory (Ferraz et al., 2011) and stress management (Giles et al., 2015). 
All catecholamines derive from L-tyrosine and contain a catechol (3,4-dihydroxyphenyl) nucleus 
and an amine group. Dopamine controls mood and emotion and modulate the “behavioural reactivity” 
of the organism, therefore reduced dopaminergic activity leads to decreased motivation, loss of 
interest, reduced activity levels (Berke and Hyman, 2000). 
Serotonin is synthesized from amino acid tryptophan and acts via two receptors, with an important 
role controlling energy intake and obesity, and also improving memory, learning and cognitive 
function (Yu et al., 2012). Serotonin is also implied on major depressive disorder (MDD) (Wang et al., 
2016; Weissman et al., 2016). 
Major depressive disorder is a complex and debilitating illness characterized by depressed mood, 
anhedonia, irritability, concentration difficulties, and abnormalities in appetite and sleep (Wang et al., 
2016). Depression is potentially fatal since it can lead to life threatening decisions, like suicide. The 
current therapy for depression involves selective serotonin reuptake inhibitors (SSRIs) and 
serotonin/norepinephrine reuptake inhibitors (SNRIs), despite the possible dopamine role on emotion 
control (Dutta et al., 2014). 
A study from Kodas et al. (2004) reported that serotoninergic neurotransmission is affected by n-3 
PUFA in a rat model. McNamara et al. (2010) found a correlation between higher levels of PUFA 
consumption and higher expression of serotonin in midbrain. Vines et al. (2012) found that adult rats 
supplemented with DHA and EPA, exhibited increased concentrations of serotonin in the frontal 
cortex and hippocampus. Guixà-González et al. (2015) found a link between dopamine receptors and 
DHA intake. Bondi et al. (2014) found that n-3 PUFA deficiency decreases dopamine availability, 
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affecting behaviour. Sublette et al. (2014) also found a relation between omega-3 PUFA intake and 
dopamine, suggesting that n-6/n-3 balance may impact depression pathophysiology through effects on 
the dopaminergic system. Zimmer et al. (2000) also reported the effects of n-3 PUFA on dopamine 
neurotransmission.  
Fish oil is rich in EPA and DHA and, given the relation between these fatty acids and 
neurotransmission, fish oil intake may promote a decrease in the incidence of depressive disorders 
(Carabelli et al., 2015; Tang et al., 2015; Grosso et al., 2014), stress and anxiety behaviours 
(Mizunoya et al., 2013; Ferraz et al., 2011). It can also promote brain development, cognitive function 
and improve memory and learning processes (Dyall, 2015; Pérez et al., 2013; Das, 2003). 
EPA and DHA comprise 30% of the fatty acids present in fish oil, but there are variations in the 
proportions of the individual EPA and DHA in different fish oils. For example, cod liver oil is richer 
in EPA, whereas tuna oil is richer in DHA (Calder, 2012). Is not clear yet if the benefits associated to 
the consumption of fish oil are specific of one of the precursors (EPA or DHA) or come as the 
combination and interaction of both fatty acids (EPA+DHA) (Song et al., 2016; Russell and Bürgin-
Maunder, 2012), since the current studies only focus on one of the fatty acids and do not evaluate in a 
comparative way the role of the three possible forms. Besides, those studies often present 
contradictory results (as it will be stated next), which increase the need to clarify the role of LC-PUFA 
metabolites. 
 
1.3.2. Role of EPA 
Eicosapentaenoic acid intake alone has been associated to a reduced risk of all-cause mortality 
(Inoue et al., 2015). In a comparative trial, it was seen that a supplementation rich in EPA promoted a 
better cognitive performance than a supplementation rich in DHA, indicating a more effective role of 
EPA in enhancing neurocognitive functioning (Bauer et al., 2014). In an opposite way, prior studies 
reported EPA to increase the severity of depression (Adams et al, 1996), but in more recent studies, 
EPA was reported to have a useful role in schizophrenia (Das, 2003) and benefit effects in mood 
disorders (Song et al., 2016; Dyall, 2015).  
 
1.3.3. Role of DHA 
Docosahexaenoic acid is essential for the growth and functional development of the brain in infants 
and is also required for maintenance of normal brain function in adults (Salemet al., 2015; Bradbury, 
2011).  
Current evidence suggests that consumption of DHA may enhance cognitive performance relating 
to learning, cognitive development, memory and speed of performing cognitive tasks, by increasing 
hippocampal acetylcholine (Ach) levels in brain (Stonehouse, 2014; Minami et al., 1997), whereas 
decreases in DHA levels in the brain are associated with deficits in synaptic circuits’ maturation and 
functional plasticity (Haghighi et al., 2015), cognitive decline during aging and with the onset of 
sporadic Alzheimer disease (Dyall, 2015; Horrocks and Yeo, 1999). DHA can also reverse age-related 
impairment on brain and restore some neurochemical abnormalities to normality (Das, 2003).  
According to Pusceddu et al. (2016), DHA seems to be more of benefit in both memory and 
cognition than EPA, or their combination, as observed in adulthood, possibly due to the phospholipids 
degradation occurring at this last stage of life.  
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The role of DHA in depressive-like disorders, however, is less clear. Studies from Levant (2013) 
and Bradbury (2011) found evidences of a benefit DHA role on major depression, whereas Song et al. 
(2016) didn’t found an association between DHA and reduced depressive scores. 
 
1.3.4. Combined EPA and DHA role 
The majority of the LC-PUFA benefits already stated were reported to be associated with an 
EPA+DHA diet. However, the exact role of each fatty acid in neuroimmune modulation and 
neurogenesis, the interaction between EPA and DHA and the best EPA/DHA ratio for improving brain 
disorders remain contorverse. It is also unknown whether EPA, as a DHA precursor, acts directly or 
via DHA (Song et al., 2016; Dyall and Michael-Titus, 2008). However, there are evidences supporting 
both independent and shared effects of EPA and DHA that need to be deeper study (Dyall, 2015). 
An EPA+DHA diet has been reported to be involved in eye-hand coordination (Dunstan et al., 
2008), to reduce biochemical disorders and oxidative stress in brain (Saada et al., 2014), have a 
protective role in Alzheimer's disease (Boudrault et al, 2009), multiple sclerosis (Jelinek et al., 2013), 
Huntington’s and Parkinson’s disease (Dyall and Michael-Titus, 2008). However, the main evidence 
for EPA+DHA diet has been observed in mood disorders and in the treatment of conditions 
characterized by a high level of impulsivity, aggression and personality disorders, mainly due to the 
action of the monoamine and catecholamines systems, previously described. In patients with attention 
deficit hyperactivity disorder (ADHD), small-to-modest effects of LC-PUFA have also been found 
(Bozzatello et al., 2016; Appleton et al., 2010). 
Since the majority of studies reporting EPA and DHA effects are related with depressive state, 
stress and anxiety, it is important to distinguish the specific role of each PUFA metabolites in 
promoting more active and mood-benefit behaviours. 
 
 
1.4.  Behavioural tests 
There are several behavioural tests to measure the level of activity, or the active/passive state, in 
rats. Those tests can be performed in multiple experimental sets, including testing the effects of a 
specific diet in modulating behaviour.  
  Open Field Test (OFT) is performed essentially to assess the locomotor activity and 
exploratory behaviour of rats and is used as an operational index of anxiety-relevant behaviours (Wu 
et al., 2016; Appleton et al., 2015); 
  Anxiety-like behaviours and exploratory movements can also be assessed by Elevated plus 
Maze Test (EPM) (Appleton et al., 2015; Mizunoya et al., 2013); 
  Tail-suspension Test (TST) is used to score movements of agitation and immobility (Steru et 
al., 1985).  
  Light–dark Transition Test (LDT) scores the time spent on dark or light areas to assess 
anxiolytic behaviours in mice (Mizunoya et al., 2013); 
  The Novelty-Suppressed Feeding Test (NSFT) is a behavioural test used to assess anxiety-
like behaviour (Venna et al., 2009); 
  Depression-like behaviour, behavioural despair and activity state in the animals are majorly 
assessed by a Forced Swimming Test (FST) (Das et al., 2015; Arbabi et al., 2014), that can also be 
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used to evaluate the effects of the administration of different diets, antidepressant drugs and new 
compounds on rats (Can et al., 2012), therefore being the best suited test to apply in this experiment. 
 
1.4.1. Forced Swimming Test 
One way of measuring the state of activity in laboratory animals is the Forced Swimming Test 
(FST). This is the most commonly used test in neurobiology and genetic research and allows scoring 
active/passive behaviours in rats. Besides, is the least stressful test for the animals compared to the 
other behavioural tests (Mizunoya et al., 2013). 
Rats are placed in an inescapable transparent tank that is filled with water and their escape related 
mobility behaviour is measured. The rat FST is usually conducted in two sessions: a 15-min pre-test 
session on day 1 and a 5-min test session on day 2. The ‘‘behavioural despair’’ is defined as an 
animal’s reaction to the inability to escape from a stressful environment (Huang et al., 2008), which 
induces a characteristic behaviour of immobility in the second FST. The development of immobility is 
usually facilitated by the 15 minute pre-test, where rats are initially highly active, vigorously 
swimming in circles, trying to climb the wall or diving to the bottom. After 2-3 min test, activity 
begins to slow and the animals tend to produce a characteristic behaviour called floating, in which the 
rat makes only those movements necessary to keep its head above water, progressing for immobility 
behaviour. The immobility increased when the rats were subjected to the 5-min test session of forced 
swimming 24 hours later. (Lakhwani et al., 2007). The “behavioural despair” is, thus, learned 
helplessness and can be modulated by antidepressant agents (Wibrand et al., 2013). 
The forced swimming test is straight forward to conduct reliably since it requires minimal 
specialized equipment, is a relatively short and low cost behavioural test that and it’s not necessary to 
prior training the rats .It is the most adequate test for comparison between different strains of rats or 
different exposures of the same strain to different environments, drugs or diets. The FST has also 
proven to be useful in basic research related to the neurobiology and genetics of mood disorders, since 
the behaviours measured can differentiate between serotonin and norepinephrine acting compounds 
(Can et al., 2012). 
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1.5.  Objectives 
The underlying hypothesis of this work was that EPA and DHA have different behavioural effects 
and, therefore, it would be possible to improve animals’ active behaviours differentially, in order to 
achieve a tailor-made therapy for activity-related disorders. 
Hence, the main goal of this work was to evaluate, in a comparative way, the potential benefit of 
dietary LC-PUFA intake in modelling animals’ behaviour. The role of individual EPA, individual 
DHA and the combined form EPA+DHA was discriminated and compared to determine which diet 
and type of fatty acid is more beneficial to increase active behaviours in Wistar rats. EPA was 
provided by a diet based on Nannochloropsis microalgae extract; DHA come from a Schizochytrium 
algae extract; the combined EPA+DHA form was provided by fish oil. A diet without EPA or DHA 
was used as a negative control for active behaviours. 
The specific objectives were to assess the active/passive state of the animal through a behavioural 
FST and complement the results with the measure of biological and growth parameters, biochemical 
analysis of plasma and fatty acids present in faeces, erythrocytes and brain, as well as determinate the 
serotonin and catecholamines levels in red blood cells. The biological and growth parameters show if 
there are any differences among the animals of each group and will also be compared with reference 
values to determine the effects of diet on those parameters. Biochemical analysis of plasma evaluates 
several parameters related to normal function of organs, and rat’s organism in general, to see any 
differences caused by the experimental diets. The fatty acid profile on faeces was measured to 
determine the loss of fatty acid through faeces, compared to the amount given by the diet. The fatty 
acid profile in erythrocytes and brain was used as a systemic indicator of the absorption of fatty acid in 
the rats’ organism. Finally, serotonin and catecholamines levels were measured to detect if the 
different diets induce differences in the neurotransmitters’ function. 
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2. Materials and methods 
 
2.1.  Animals sampling and experimental design 
All procedures involving animals were conducted in accordance with ethical guidelines and with 
approval from the Ethics Commission of CIISA/FMV and the Animal Care Committee of the National 
Veterinary Authority (Direcção Geral da Alimentação e Veterinária, Portugal), following the 
appropriate European Union guidelines (N. 86/609/EEC/2010/63/EU Directive). The experimental 
assay and euthanasia procedures were performed by project members certified for animal handling 
(category C by FELASA). In order to minimize animal suffering, the minimum number of animals and 
duration of observations were employed to gain reliable data. 
Thirty-two male Wistar rats, randomly divided into four dietary groups, with eight animals per 
group, were used in this study. Rats were eight weeks old and weighted an average of 260g when 
purchased. They were allowed 14 days to acclimatize to the laboratory conditions prior to the 
experiment and were fed with a commercial standard diet during that time. The average weight of the 
animals after the acclimatize period was 300g.  
At the beginning of experimental procedures, the animals were housed one per cage, in standard 
cages (33×23×12cm) under a 14/10 hour light/dark cycle schedule, with the light cycle according to 
natural daylight. They were kept under standard animal house conditions, in a controlled temperature 
room of 20°C-24°C, in a certified animal house in Faculty of Veterinary of Lisbon University. They 
were fed with the experimental diets after the two weeks acclimatize period and were given ad libitum 
access to food and water, except during weights and behavioural tests. 
The animals were weighed twice a week on a digital scale and food intake was calculated by the 
difference between the weight of the remaining food on the pellets and the weight of the food added 
prior. The behavioural tests were carried out nine weeks after the beginning of experiment, which 
lasted for 10 weeks (excluding adaptation period). 
At the end of the experimental period, rats were fasted for 12hours, weighted before and after the 
fasting period, and euthanized by guillotine decapitation under anaesthesia with isoflurane, in certified 
ethical conditions that minimized animal suffering.  
Organs and blood were collected after euthanasia. The carcass, kidney, lungs, heart, testicle and 
spleen were weighted and stored in vacuum at -80°C. Muscle, fats, liver, brain and hippocampus were 
put into a cryotube and after a bath in liquid nitrogen were stored at -80°C. 
Blood was collected into two 4 ml Sarstedt tubes with Li-heparin and centrifuged at 1500 xg, 4°C, 
for 15 min. One of the tubes was stored at -80°C for future biochemical analysis and the other was 
used to separate red blood cells, following the procedure: 
1. Blood was placed into an eppendorf, washed 3x with sterile saline solution and 
centrifuged again in the same conditions already stated; 
2. After centrifugation, the supernatant was discarded; the eppendorf was washed again in 
the same conditions and centrifuged for the third time; 
3. After a second supernatant exclusion, the red blood cells were collected with a Pasteur 
pipette, stored in a cryotube bathed in liquid nitrogen and freeze at -80°C. 
All diets were collected after the experimental period and stored in vacuum bags at -80°C to 
determine their nutritional value (see 2.6. FAME determination). Faeces were also collected and stored 
 13 
 
in vacuum bags at -80°C to further analyse their fatty acid composition (see 2.6. FAME 
determination). 
Table 2.1 shows the chronogram for the 10 week experimental period plus the 2 week previous 
acclimatization period. 
 
Table 2.1 Experimental design for the 12 weeks 
Acclimatize period 
(2 weeks) Week 1 Week 2 Week 3 Week 4 
Animals' purchase; 
3rd weighing 
Start of 
experiment; 
4th weighing 
5th and 6th weighing 7
th
 and 8th 
weighing 
9th and 10th 
weighing 
Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 
11th and 12th 
weighing 
13th and 14th 
weighing 
15th and 16th 
weighing 
17th and 18th weighing; 
Faeces collecting 
19th and 20th 
weighing; 
FST 
21st and 22nd 
weighing; 
Euthanasia 
 
2.2.  Diets 
Diets were manufactured by the Experimental Diets Unit from the University of Almeria. The 
proximate chemical composition of the diets was determined according to Association of Official 
Agricultural Chemists (AOAC), and fatty acid composition was assessed as described by Bandarra et 
al. (2001). All diets were based on the standard AIN-93M formulation for rodents, with modified lipid 
fractions.  
The detailed design for the different experimental diets is stated as follows: 
A. Milk fat diet (Milk Fat group): negative control diet, with 20% of fat: 12% from milk and 8% 
from soybean oil; 
B. Milk fat with Cod Liver Oil diet (Fish Oil group): positive control diet, with 20% of fat: 12% 
from milk, 4% from soybean oil and 4% from cod liver oil which is rich in eicosapentaenoic acid 
(20:5n-3, EPA) and docosahexaenoic acid (22:6n-3, DHA); 
C. Milk fat with Nannochloropsis microalgae diet (Nanno group): experimental diet, with 20% 
of fat: 12.5% from milk fat, 5.9% from soybean oil and 2.4% from Nanno oil, an autotrophic 
microalgae rich in eicosapentaenoic acid (20:5n-3, EPA); 
D. Milk fat with Schizochytrium algae diet (Schyzo group): experimental diet, with 20% of fat: 
12.2% from milk fat, 6.5% from soybean oil and 1.8% from Schyzo oil, rich in docosahexaenoic acid 
(22:6n-3, DHA). 
Milk fat, rich in saturated fatty acids, and soybean oil are present in all four experimental diets, 
which differ among them by having LC-PUFA added in the form of EPA+DHA (Fish oil group), EPA 
(Nanno group) or DHA (Schyzo group). Milk Fat group is the negative control group for active 
behaviours, since it doesn’t have EPA or DHA added. Fish oil group, on the other side, is the positive 
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control group for active behaviours, since it has both EPA and DHA added. Nanno and Schyzo groups 
are the experimental groups in test to evaluate EPA and DHA isolated properties. 
Table 2.2 shows the percentage of each ingredient used in the four diets, which were adjusted to be 
isoenergetic in order to be statistically compared. The chemical composition (g/100 g and kcal/100 g) 
of the diets was estimated (in general) and is presented in table 2.3. 
 
Table 2.2 Ingredients used in the four diets (%) 
Ingredients Milk Fat Fish Oil Nanno Schyzo 
Casein 14 14 10.8 12.5 
Corn starch 37.8 37.8 39.2 38.4 
Maltodextrin 7 7 7.3 7.1 
Sucrose 10 10 10.4 10.1 
Cellulose 5 5 5.2 5.1 
Soybean oil 8 4 5.9 6.5 
Milk fat 12 12 12.5 12.2 
Fish oil (Cod liver oil) . 4 . . 
Nanno oil . . 2.4 . 
Scyz oil . . . 1.8 
Cholesterol 1.25 1.25 1.3 1.27 
L-Cysteine 0.2 0.2 0.2 0.2 
Mineral AIN-93M mix 3.5 3.5 3.6 3.6 
Vitamin AIN-93M 
mix 1 1 1 1 
Choline bitartrate 0.2 0.2 0.3 0.3 
TBHQ (antioxidant) 0.001 0.001 0.001 0.001 
 
 
Table 2.3 Chemical composition of the diets in g/100g and kcal/100g (estimated) 
Chemical composition (g/100g) 
Protein 10,1 
Fat 20 
Fibre 3,8 
Moisture 5,6 
Ash 3,1 
Carbohydrate 57,4 
Energy (kcal/100g) 450 
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Table 2.4 shows fatty acid profile present in the oils used in each diet, which were adjusted to have 
a similar total n-3, so the differences found could be associated with the type of omega-3 used instead 
their percentage in diet. Oils used in diet do not reflect the final fatty acid composition of the diet, 
since diets have other ingredients besides oil. 
 
Table 2.4 Fatty acid composition of oils used in the four diets (%) 
Fat Acids in Oils Milk Fat Fish Oil Nanno Schyzo 
12:0 6 . . 16.7 
14:0 12 4.8 6 7.5 
15:0 0.1 0.4 . . 
16:0 31 10.7 28.7 6.2 
16:1n7 4 8.3 30 16.7 
18:0 11 4.3 1.5 
 
18:1n9 24 16.5 21.8 36.2 
18:1n7 0.2 4.7 . . 
18:2n6 3 1.7 2.3 27.7 
18:3n6 . 0.2 . . 
18:3n3 1 0.7 3 . 
18:4n3 . 2.4 . . 
20:00 0.3 . . . 
20:1n9 0.1 13.3 . . 
20:4n6 . 0.3 5 . 
20:4n3 . 0.7 . . 
20:5n3 . 8.8 15 . 
22:1n11 . 7.6 . . 
22:4n6 . 0.5 . . 
22:5n6 . 0.3 . . 
22:5n3 . 1.2 . . 
22:6n3 . 10.9 . 47 
 
 
Table 2.5 shows the fatty acid profile and total sums of fatty acids (%) in each experimental diet 
after chemical analysis (see 2.6. FAME determination). Diets formulation was based on similar total 
n-3 among diets in order to be statistically compared. 
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Table 2.5 Fatty acid profile of each diet and total sums (%)  (Continues next page) 
Fatty acids in diet Milk Fat Fish Oil Nanno Schyzo 
11:0 3.17 3.21 2.93 2.65 
13:0 0.10 0.10 0.11 0.13 
14:0 isobr 0.09 0.09 0.13 0.07 
14:00 9.81 11.11 10.04 9.32 
15:0 isobr 0.19 0.24 0.38 0.17 
15:0 ante-iso 0.37 0.38 0.35 0.32 
15:0 0.89 0.96 0.87 2.35 
16:0 anteiso . . 0.07 . 
16:0 28.50 28.75 28.91 29.04 
16:1n9 0.13 0.15 5.33 0.12 
16:1n7 1.19 2.87 . 1.34 
17:0 isobr 0.29 0.33 0.31 0.27 
16:2n4 . 0.18 0.04 . 
17:00 0.33 0.36 0.38 0.64 
16:3n4 0.17 0.25 0.23 0.16 
17:1 . . 0.07 . 
16:4n3 . 0.05 . . 
18:0 6.95 6.87 6.32 6.67 
18:1n9 20.25 19.12 18.01 17.04 
18:1n7 0.14 1.71 0.09 1.46 
18:1n5 0.10 0.30 0.10 0.23 
19:0 isobr 0.18 0.22 0.18 0.19 
18:2n6 21.22 12.31 15.66 16.34 
18:3n6 0.09 0.11 0.04 0.08 
19:0 0.05 0.08 0.10 0.12 
18:3n4 0.02 0.06 0.04 0.03 
18:3n3 2.56 1.59 1.88 2.04 
18:4n3 0.19 0.41 0.19 0.19 
20:0 0.13 0.12 0.10 0.12 
20:1n11 0.09 . 0.09 0.10 
20:1n9 0.08 1.59 0.07 0.07 
20:1n7 . 0.04 . . 
20:2n6 0.02 0.10 0.07 0.03 
20:4n6 0.09 0.14 0.59 0.11 
20:4n3 
20:5n3 
. 
. 
0.11 
1.15 
. 
3.16 
0.08 
0.10 
22:0 0.07 0.05 0.04 0.04 
22:1n11 . 0.73 . . 
22:1n9 . 0.07 . . 
21:5n3 . 0.03 . . 
22:5n6 . . . 1.22 
22:6n3 . 1.19 . 3.30 
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Sums (%) Milk Fat Fish Oil Nanno Schyzo 
18:2n6 (LA) 21.2 12.3 15.7 16.3 
18:3n3 (ALA) 2.6 1.6 1.9 2.0 
20:5n3 (EPA) 0.0 1.1 3.2 0.1 
22:6n3 (DHA) 0.0 1.2 0.0 3.3 
Total SFA 51.1 52.9 51.2 52.1 
Total MUFA 22.0 26.6 23.8 20.4 
Total PUFA 24.3 17.8 21.9 23.7 
Total n3 2.8 4.6 5.2 5.7 
Total n6 21.4 12.7 16.4 17.8 
n3/n6 0.1 0.4 0.3 0.3 
Total 97.4 97.2 96.9 96.2 
Total FA (mg/g) 220.4 202.3 236.0 184.8 
Total FA (g/100g) 22.0 20.2 23.6 18.5 
 
 
2.3.  Forced Swimming Test 
Behavioural effects and antidepressant mechanism of n-3 PUFA can be tested using a blinded 
Forced Swimming Test (FST). This behavioural test was performed essentially according to the 
procedures described by Porsolt et al. (1977), with minor modifications. 
Each rat is placed individually into vertical Plexiglas cylinder (60 cm height and 20 cm diameter) 
containing water at 25°C (±2°C) with 30 cm deep for a 15-min pre-test. The cylinders are made of 
transparent Plexiglas, since this material is able to withstand the frequent movement of the tanks and 
possible accidents better than glass (Can et al., 2012). The water volume prevents the animal from 
escaping or touching the bottom of the cylinder. The behavioural tests are done individually, one at the 
time, to prevent a copying mechanism and avoid bias. Also, the room for the experiments has to be 
controlled so that no noises, light changing or reflexes can disturb rats’ normal behaviour. At the end 
of the pre-test phase, the rat is removed from the water, dried with a towel to avoid hypothermia and 
then returned to its cage, so it can quickly restore its normal conditions. The water is changed after 
every trial to eliminate traces of urine, faeces and odour clues left by the previous rat and thus avoid 
any influence on the next rat. Twenty-four hours later the rat is exposed to the same experimental 
conditions outlined above for a 5 min FST. This final test is recorded by a conventional video camera 
positioned in front of the Plexiglas cylinder and behavioural times are calculated later with proper 
software (ETHOWATCHER®; Crispim Junior et al., 2012). The rats’ identification is registered by a 
code in order to avoid bias during interpretation results. 
The behaviours registered during the test session, described by Porsolt et al. (1977) and Slattery 
and Cryan (2012), are stated as follows:  
  Climbing: initial intense escape-directed behaviour, with upward directed movements of the 
forepaws along the cylinder walls, non-rhythmic and agitated. Considered as a normal active 
behaviour, since the rat is fighting to escape; 
  Swimming: rhythmic paw movements throughout the cylinder, including diving. Considered 
as abnormal active behaviour, since the rat is exploring the environment in an attempt to escape; 
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  Floating: when the rat stopped all active behaviours and remained floating in the water 
with minimal movements, just to maintain its head above the water. Considered a passive 
behaviour, since the rat is doing the minimum effort to survive, without struggle or trying to 
escape;  
  Immobility: defined as absence of movement, with the body inclined forward in a 
retracted position, passively floating or even sinking, with immobile paws shrunken close to the 
body. Considered a passive behaviour and the marker for inactivity, since the rat isn’t moving or 
doing any effort to escape or even survive. The immobile behaviour is believed to reflect a 
failure to persist in escape-directed behaviour after stress. 
  Frequency (of behaviour): number of times the animal has done the referred behaviour 
in analysis; It is only a support measure, since it’s not indicative of rats’ active behaviour. 
  Latency (of behaviour): first moment (in seconds) the animal has done the referred 
behaviour. Shows the delay between the first behaviour recorded and the referred behaviour in 
analysis. Latency of immobility shows the interval of time until the rat makes the first immobile 
behaviour, which can be an indicative of the rats’ low-active state if the latency time is too low. 
This measure as never been systematically validated across laboratories and compound classes, 
but is used as a data support for the other measures (Slattery and Cryan, 2012). 
Stress triggers the normal rats’ behaviour when the animals are placed on water and consists on 
very active, sometimes uncontrolled, movements in the first minute of the test (climbing behaviour), 
then a more controlled, explorative movements (swimming behaviour), followed finally by a decrease 
in the activity of rats (floating and immobile behaviours), generally after 2 minutes test. The rats’ 
activity can hence be accessed by measuring both the time and sequence of movements (including 
latency and frequency) preformed in FST.  
Figure 2.1 illustrates the four predominant behaviours of FST, as stated above. 
 
Figure 2.1 Behaviours’ of FST: A-climbing (active upward movement); B-swimming (active lateral movement); C-
floating (passive fluctuating movement); D-immobile (absence of movement). 
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2.4.  Behavioural test analysis 
All behaviours were analysed with ETHOWATCHER® software, a certified analytical system 
(Crispim Junior et al., 2012) and a tool for behavioural and video-tracking analysis in laboratory 
animals that allows ‘real-time’ behavioural scoring directly from the ongoing events in the 
environment, from analogue video files or off-line behavioural recordings from digital video files. The 
same digital video file may be processed for automated extraction of activity-related parameters 
(location, distance travelled, angle, moving speed, approximate object area, track graph) and object 
(animal) tracking using digital image processing techniques. The software provides time-segmented 
reports on duration, frequency and latency for each behavioural unit as well as the time-referenced 
sequence of recorded behaviours, and on the activity related-indexes. These reports are synchronized 
by the same time source (the frame unit number in the video file). 
All videos had 310 seconds, but the first ten seconds were discarded to minimize bias and 
confounding variables (related to shock-adaptation period) and only the remaining 300 seconds were 
analysed. The video analysis was observed frame by frame to precisely score the time spent in each 
behaviour. Frequency was measured at each 5 seconds interval of the 300 seconds test session and 
only the predominant behaviour in those 5 seconds was recorded. Latency was automatically 
determined by the program. 
 
2.5.  Determination of plasma metabolites 
The plasma concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL), low-
density lipoprotein cholesterol (LDL), cholesterol triglycerides, glucose, creatinine, urea, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatise (ALP) and gamma-
glutamyl transpeptidase (γ-GT or GGT) were analyzed in serum using commercial diagnostic test kits 
from Roche Diagnostics (Mannheim, Germany) in a Modular Hitachi Analytical System (Roche 
Diagnostics). Very low-density lipoprotein cholesterol (V-LDL) and total lipids were calculated 
according to the formulas by Friedewald et al. (1972) and Covaci et al. (2006), respectively. 
Insulin levels were measured in plasma using a commercial ELISA kit (10-1250-01, 161 Mercodia, 
Uppsala, Sweden). The degree of insulin resistance was calculated by the homeostasis model 
assessment using the insulin resistance index (HOMA-IR) (Matthews et al., 1985):  
 Fasting serum glucose (mmol/l) X fasting serum insulin (mU/L)/22.5 
Low HOMA-IR values indicate high insulin sensitivity, whereas a high HOMA-IR value indicates 
high insulin resistance.  
 
2.6.  Determination of fatty acids 
The fatty acid composition of the food, faeces, erythrocytes and brain were analysed. Fatty acid 
methyl esters (FAME) were prepared according to the method of Bandarra et al. (2001), with minor 
modifications. 
Samples were lyophilized (260°C and 2.0 hPa) to a constant weight. FAME were obtained by 
adding 5 mL of acetyl chloride and anhydrous methanol mixture in a 1:19 proportion, swirling for 1 
minute in a vortex and placing the contents in a 80°C bath for 1 hour. The acetyl chloride and 
anhydrous methanol mixture produces an exothermic reaction, so the regents were carefully added in 
an ice tray, placed in a hood. 
 20 
 
After the bath and a 30 min cooling time, it was added 1 ml of ultra-pure H2O mili-Q and 2 ml of 
n-heptane to the tubes containing the mixture, that were then centrifuged at 3000 xg for 3 min. The n-
heptane layer was then collected with a Pasteur pipette and filtered with anhydrous sodium sulphate 
into vial tubes. 
FAME were concentrated to a final volume of 200 μL in n-heptane, and 2 μL of the sample was 
injected on a DB-Wax capillary column (30 m × 0.32 mm internal diameter × 0.25 μm film thickness; 
J&W Scientific, Folsom, CA, USA) in a Varian CP-3800 gas chromatograph (Varian, Palo Alto, CA, 
USA) equipped with a flame ionization detector (Varian). The injector and detector temperatures were 
set at 250°C. The adequate separation of FAME was achieved over a 40 minute period, with 5 minutes 
at 180°C, followed by an increase of 4°C/min until 220°C, and keeping the sample at this temperature 
for 25 minutes.  
The quantification of total fatty acid was based on the internal standard technique, using the 
heneicosanoic acid (21:0). Authentic standards were used for fatty acid identification. Total and 
individual fatty acids were expressed as percentage of the total fatty acid. 
 
2.7.  Determination of serotonin and catecholamines 
Plasma serotonin levels were determined using a commercial kit from ClinRep (GmbH 
Labortechnik, Munich, Germany) by high-performance liquid chromatography (HPLC) with 
electrochemical detection, following the procedure: 
  200 μL of plasma are placed in a flask sample preparation and subsequently marked with the 
internal standard. Then adds a precipitation reagent and the sample mixture is briefly vortexed. To 
remove the precipitant (sample matrix), the sample is centrifuged. An aliquot of the supernatant can 
then be injected into the HPLC system. 
  For the chromatographic separation is used a special reverse phase column. The analytes are 
measured by an electrochemical detector and are quantitatively evaluated using the internal 
standard method. 
HPCL conditions for serotonin analysis are defined as follows: 
  Flow rate: 1.0 mL / min 
  Injection volume: 20 μL 
  Injection interval: 10 min 
  Column heater at 30 °C  
  Column pressure at 200 bar, maximum value. 
  Detector: 450 mV 
Catecholamines levels were determined using a commercial Bio-Rad kit (p-Catecholamines by 
HPLC reagent kit, 100 tests; 195-5880) by HPLC with electrochemical detection and employing 
alumina extraction, following the conditions: 
  Sample volume: 50 μL 
  Temperature: 35 °C 
  Detector: 0.55 V 
  Flow rate: 0.7 ml/min 
  Duration of chromatography: 19.5 min 
  Peaks: 1-norepinephrine; 2-epinephrine; 3-dopamine 
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2.8.  Statistical analysis 
Statistical analyses were carried out with the Statistical Analysis Systems (SAS) software package, 
version 9.3 (SAS Institute, Cary, NC, USA). All data were checked for normal distribution and 
variance homogeneity and reported as means ± standard deviation (SD), after outlier removal with the 
outlier formula: 
 (Q1 – 1.5*IQR ; Q3 + 1.5*IQR) 
The mean scores were analysed by one-way analysis of variance (ANOVA) for all biological and 
biochemical parameters in test and also for all the behaviours measured. This analysis was followed by 
a Tukey’s multiple comparisons test and value of p<0.05 was considered to be statistically significant. 
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3. Results and discussion 
 
3.1.  Growth parameters 
Table 3.1 shows the average weight of the animals of each group at the beginning and at the end of 
the experiment, the total and daily feed intake in each group (average) and also shows tissues and 
carcass weights after euthanasia.  
 
Table 3.1 Feed intake and body composition parameters (g) 
 
Milk Fat Fish Oil Nanno Schyzo 
 
Mean SD Mean SD Mean SD Mean SD Significance 
Daily feed intake 
Total feed intake 
21.01 ab 
1323 a 
0.876 
55.068 
19.64 c 
1237 b 
0.873 
53.935 
21.80 a 
1375 a 
0.986 
61.872 
19.65 bc 
1217 b 
1.288 
59.533 
0.001 
0.001 
Initial body weight 300.6 13.768 300.8 21.240 301.8 13.119 299.9 13.819 0.995 
Final body weight 459.6 30.188 448.6 36.997 459.8 29.518 426.0 23.929 0.062 
Total weight gain 159.0 a 18.641 147.9 ab 20.311 152.1 ab 15.995 129.2 b 16.906 0.020 
Carcass 
Dorso-lateral muscle 
Epididymal fat 
Retroperitoneal fat 
Heart 
Lungs 
Liver 
198.9 ab 
6.264 
6.006 
4.616 
1.074 
1.435 
13.574 
10.558 
0.959 
1.826 
1.851 
0.077 
0.125 
1.942 
194.9 ab 
6.710 
5.590 
4.054 
1.149 
1.426 
13.316 
14.783 
1.148 
1.444 
1.145 
0.174 
0.124 
1.517 
201.3 a 
6.543 
6.201 
4.631 
1.109 
1.347 
13.751 
9.724 
0.779 
1.299 
0.846 
0.120 
0.213 
1.566 
184.8 b 
6.656 
5.210 
4.535 
0.978 
1.359 
13.772 
11.955 
0.908 
0.870 
1.168 
0.109 
0.123 
1.371 
0.046 
0.809 
0.315 
0.712 
0.070 
0.523 
0.931 
Spleen 
Kidney 
Testicle 
Brain 
Hippocampus 
0.663 
1.268 ab 
1.702 
1.476 
0.392 
0.045 
0.157 
0.143 
0.100 
0.033 
0.656 
1.143 b 
1.762 
1.463 
0.433 
0.109 
0.049 
0.111 
0.088 
0.071 
0.694 
1.288 a 
1.749 
1.417 
0.401 
0.097 
0.087 
0.088 
0.085 
0.038 
0.660 
1.183 ab 
1.709 
1.454 
0.414 
0.060 
0.126 
0.117 
0.062 
0.089 
0.479 
0.003 
0.682 
0.588 
0.533 
 
The difference between initial and final weights of the animals (total weight gain) is statistical 
different in Milk Fat group compared to Schyzo group (159.0 g and 129.2 g, respectively; p=0.02), but 
Fish Oil (147.9 g) and Nanno (152.1 g) groups did not show a significant difference compared to the 
other two groups (p>0.05).  
Since all diets had the same amount of fats in order to be compared with each other, it was 
expected that the weight gain was not significant different between the groups. This result, however, 
can be explained with the amount of food ingestion. As can be seen in Table 3.1, the total feed intake 
is higher in Milk fat (1323 g) and Nanno (1375 g) groups than in Fish Oil (1237 g) and Schyzo (1217 
g) groups (p<0.01). The daily feed intake is also different in all groups (p<0.01), being higher in 
Nanno group (21.80 g) and lower in Fish Oil group (19.64 g). A higher intake of food can lead to a 
higher final height, with Nanno group being the one with a higher total ingestion and final weight and 
Schyzo group the one with the lower food ingestion and also a lower final weight. 
Kidney (p=0.003) and carcass (p=0.046) also show significant differences between the groups. 
Carcass weight has higher values for Nanno group (201.3 g) and lower figures for Schyzo group 
(184.8 g), which is in accordance with the final weight measured during the experiments. Kidney 
weight is also higher in Nanno group (1.288 g) and it is lower in Fish Oil group (1.143 g). The reason 
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for kidney higher values could be due to an increased kidney function, possibly depending on the type 
of fatty acid given in the diet (Caligiuri et al., 2013).  
 
 
3.2.  Forced Swimming Test 
Table 3.2 shows the behaviour times (in seconds), latency (in seconds) and movement frequency 
(number of movements) of the rats during FST. Only floating time, immobile time, immobile latency, 
immobile frequency and total frequency presented statistical significant differences (p<0.05), which 
can be better observed in Figure 3.1. 
 
Table 3.2 Behavioural parameters in FST 
 
Milk Fat Fish Oil Nanno Schyzo 
 
 
Mean SD Mean SD Mean SD Mean SD Significance 
Climbing (s) 59.55 27.56 75.50 28.59 56.97 39.59 68.33 40.22 0.628 
Swimming (s) 119.22 56.75 124.47 68.61 82.13 35.27 135.16 52.93 0.110 
Floating (s) 58.35 ab 23.67 37.75 b 15.41 78.85 a 40.15 67.78 a 15.71 0.006 
Immobile (s) 67.68 ab 54.14 58.78 ab 60.35 75.98 a 38.30 24.78 b 16.83 0.006 
Total movement (s) 178.77 61.38 199.98 73.74 150.23 64.24 207.92 25.32 0.137 
Total immobile (s) 126.04 60.51 104.45 72.88 154.83 63.99 96.69 24.40 0.125 
Immobile latency (s) 31.72 b 9.58 103.69 ab 77.87 81.31 ab 55.75 130.66 a 86.09 0.001 
Climbing frequency 12.13 5.28 15.00 5.81 11.63 8.55 14.63 8.81 0.670 
Swimming frequency 26.00 13.22 25.63 14.67 19.25 9.92 27.88 10.27 0.374 
Floating frequency 9.50 5.66 6.29 3.30 14.38 9.21 11.33 3.93 0.041 
Immobile frequency 12.38 ab 12.77 11.38 ab 13.55 19.17 a 3.54 5.75 b 5.39 0.001 
Total Frequency 79.38 a 26.53 46.71 b 11.43 72.75 a 2.87 70.50 ab 22.83 0.001 
 
Floating time is lower and statistically different in Fish Oil group (37.75s) compared to the Nanno 
and Schyzo groups (78.85s and 67.78s, respectively; p=0.006) and is similar with Milk fat group 
(58.35s; p>0.05). Moreover, Milk Fat group is similar with both Nanno and Schyzo groups (p>0.05). 
Immobile time is higher for Nanno group (75.98s) and lower for Schyzo group (24.78s). Milk Fat 
and Fish Oil groups are statistically similar with both Nanno and Schyzo groups, despite these last two 
being different (p=0.006). 
It was expected for Milk Fat group to have the highest immobile and floating times, since these 
behaviours are considered as passive and non-active indicators, respectively (Porsolt et al., 1977; 
Slattery and Cryan, 2012), and Milk Fat group is the negative control group for active behaviours in 
this work. Fish Oil, on the contrary, was expected to have low times of floating and immobile, since it 
was the positive control group for active behaviours. Both Nanno and Schyzo groups were the 
experimental groups being tested, to see if their behavioural times were similar or different compared 
with each other and with Fish Oil group. 
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Forced Swimming Test 
 
Figure 3.1. Behavioural differences of each group in FST (with movements and latency in seconds and 
frequency in times). 
 
The results clearly indicate that Nanno and Schyzo groups are similar with each other and different 
from Fish Oil group regarding the floating time (p=0.006), having higher values than Fish Oil group. 
This could possibly indicate that EPA and DHA diets alone are not as benefit as an EPA+DHA diet. 
Moreover, both Nanno and Schyzo groups are similar to Milk Fat group in floating time, which can 
indicate that the diets of these groups have a similar effect as Milk Fat group diet. The only setback of 
these results is that floating time is also statistically similar between Milk Fat and Fish Oil groups, 
indicating a common benefit effect of both diets. A possible explanation for these contradictory results 
can be related to an incorrect analysis of behaviours’ times or due to an internal variability, inherent to 
the animals themselves, that is not related to diet. 
The results also show a clear difference between Nanno and Schyzo groups regarding immobility 
time (p=0.006). Nanno group is statistically similar with Milk fat and Fish oil groups, which in turn 
are also similar with Schyzo group. DHA is referred as a possible nutrient in retarding depression and 
anxiety-like behaviours, which is supported by the results present in this study, regarding to the lower 
immobility time in Schyzo group. Only Milk Fat immobility time is higher than expected and not 
consistent with the results present in other studies (Park et al., 2012; Ferraz et al., 2012), or with the 
hypothesis initially proposed.  
Immobile latency is higher in Schyzo group (130.66s) and lower in Milk Fat group (31.72s). 
Latency reflects the first moment at which the animal does the referred behaviour for the first time. 
Despite this measure is not used as an activity index, it can be used to evaluate in a comparative way 
the “lack of motivation” or “behavioural despair”, in which rat loses hope to escape the environment 
and, therefore, induce an early immobile behaviour (Pitychoutis et al., 2014; Huang et al., 2008). In 
this case, Milk Fat group has lower latency levels compared to the other groups (rich in LC-PUFA) 
which can indicate a positive benefit effect of EPA and DHA in increasing latency times and, 
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therefore, reducing immobile times (by doing immobility later, it gives less time to be immobile, 
compared to the other behaviours). 
Immobile frequency presents higher values for Nanno group (19.17) and lower for Schyzo group 
(5.75). Milk Fat (12.38) and Fish Oil (11.38) are both statistically similar with Nanno and Schyzo 
(p>0.05), despite this two are different (p=0.001). 
Total frequency is higher and similar between Milk Fat (79.38), Nanno (72.75) and Schyzo (70.50) 
groups (p>0.05). Fish Oil presents the lowest frequency times (46.71) and it’s only similar with 
Schyzo group (p>0.05). 
Behavioural frequency is not a measure for activity state, but it can show how many times the 
animal alternate between the different behaviours. Regarding immobile frequency, higher values 
means the animal often preformed immobile behaviour, which could possible indicate a higher 
tendency for the animal to be less active. A higher total frequency is not directly related with more 
activity, only tells that the animal alternate more between the behaviours, but the sequence of 
behaviours performed could tell if the animal is actually tending to more active or passive behaviours. 
Comparing total frequency with total movement, it can be seen that higher frequencies occur in groups 
with lower movement times (Milk Fat and Nanno groups) and lower frequencies occur in groups with 
higher movement times (Fish Oil e Schyzo groups). Nevertheless, further studies need to be done in 
order to found valid correlations between frequency and active/passive state. 
 
3.3.  Plasma biochemical metabolites 
The plasma biochemistry profile is presented in Table 3.3. HDL, creatinine and total proteins did 
not present a statistical difference among the groups (p=0.327; p=0.061; p=0.187 respectively) and the 
values are in accordance with the averages given by Kaneko et al. (2008) (mean ± standard deviation 
for creatinine: 1.59±0.79 mg/dl; total proteins: 75.2±2.7 g/dl; HDL: no reference values).  
Kaneko et al. (2008) is the reference chosen for comparisons of biochemical parameters in this 
work.  
Total lipids levels are statistically different between Milk Fat group and the other three groups 
(p=0.001), despite all diets had the same amount of lipids in their constitution. Milk Fat presents the 
higher values for total lipids (395 mg/dl) and Fish oil the lowest (320 mg/dl). Nanno and Schyzo group 
are statistically similar (327 mg/dl and 340 mg/dl, respectively; p>0.05) but Nanno group is also 
statistically similar with Fish Oil. A diet rich in EPA+DHA form seems to lower total lipids levels in 
plasma, and a diet rich in EPA tends to present similar results as the EPA+DHA diet, contrary to a 
DHA diet,  so the benefit effects may be due to EPA action. 
Total cholesterol levels are statistically similar between Fish Oil (50.4 mg/dl) and Nanno (54.5 
mg/dl) groups (p>0.05), Nanno having the lowest values, but is different in Milk fat (67.3 mg/dl) and 
Schyzo group (61.9 mg/dl) (p=0.001). According to Kaneko et al. (2008) the reference values for 
cholesterol in rats are 28.3±13.7 mg/dl. The results in this study are higher than the reference, which 
was expected since all diets had milk fat, rich in cholesterol. Some studies refer the potential effect for 
EPA and DHA to reduce cholesterol levels (Werman et al., 2003; Boudrault et al., 2009; Noori et al., 
2011), so it would be expected Nanno and Schyzo groups to have lowered cholesterol, which did not 
happened. This can be due to the fact that diets given to those groups only had EPA or DHA, instead 
of the combined form EPA+DHA. This hypothesis is in accordance with the results presented in this 
work, since Fish oil group had a diet rich in both EPA+DHA form and was the one with lower levels 
of total cholesterol.  
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Table 3.3 Plasma biochemistry profile and hepatic markers 
 
Milk Fat Fish Oil Nanno Schyzo 
 
 
Mean SD Mean SD Mean SD Mean SD Significance 
Total lipids (mg/dl) 
Total Cholesterol (mg/dl) 
395 a 7.274 320 c 2.510 327 bc 8.476 340 b 10.35 0.001 
0.001 67.3 a 3.284 50.4 c 3.815 54.5 c 2.878 61.9 b 3.980 
HDL (mg/dl) 13.6 1.408 12.4 2.560 12.4 1.598 13.4 1.685 0.327 
LDL (mg/dl) 32.2 b 1.669 24.0 d 2.683 28.5 c 2.106 35.3 a 1.939 0.001 
V-LDL (mg/dl) 21.8 a 0.622 14.0 b 0.862 13.6 b 1.050 13.2 b 0.668 0.001 
LDL/HDL 2.33 b 0.119 2.01 b 0.403 2.34 ab 0.315 2.66 a 0.193 0.004 
Triglycerides (mg/dl) 109 a 3.109 70.0 b 4.309 68.1 b 5.249 66.0 b 3.338 0.001 
Glucose (mg/dl) 174 a 6.089 150 b 5.780 136 c 8.008 129 c 9.296 0.001 
Creatinine (mg/dl) 0.26 0.021 0.255 0.026 0.25 0.024 0.28 0.035 0.187 
Urea (mg/dl) 28.5 c 2.878 33.8 b 3.059 32.3 bc 3.694 41.5 a 3.423 0.001 
Total proteins (g/dl) 6.825 0.191 6.663 0.311 6.838 0.185 6.613 0.181 0.061 
AST (U/l) 112 c 13.948 141 b 14.88 81.3 d 6.364 184 a 20.01 0.001 
ALT (U/l) 44.3 a 6.777 50.6 a 3.623 36.4 b 4.207 50.5 a 8.536 0.001 
ALP (U/l) 94.6 b 5.630 129.9 a 18.61 85.9 c 5.167 78.8 d 6.985 0.001 
γ-GT (U/l) 2.10 a 0.311 2.19 a 0.254 0.44 c 0.320 1.10 b 0.224 0.001 
 
DHA seems to have no effect lowering LDL by itself, since Schyzo group presents the higher 
values of LDL (35.3 mg/dl). Fish Oil group, in contrast, has the lowest levels for this lipoprotein (24.0 
mg/dl), which can again be due to the combined effect of EPA+DHA diet.  
VLDL presents the highest levels in Milk Fat group (21.8 mg/dl), which was expected since the 
diet of this group does not have EPA or DHA that can help lower VLDL levels. The levels of VLDL 
for the other three groups were statistical similar (p>0.05). 
Triglycerides levels are higher and statistical different for Milk Fat group (109 mg/dl) compared to 
the other three groups (70.0; 68.1; 66.0; p=0.001), which was again expected as the Milk Fat diet does 
not have EPA or DHA to help lower the levels, but all values are in accordance with the reference 
values given (173.3 ± 25.9 mg/dL).  
Glucose levels are also different between the groups (p=0.001), being higher in Milk Fat group 
(174 mg/dl) and lower in Nanno and Schyzo groups (136 mg/dl and 129 mg/dl respectively). The 
reference values for glucose in rats are 73.3 ± 18.2 mg/dl, so the results in this study are higher than 
the reference. A study from Holness et al. (2003) reports that EPA and DHA affect glucose 
metabolism, creating insulin resistance, which can help explaining this augmented glucose levels. 
Urea levels are higher in Schyzo group (41.5 mg/dl) and lower in Milk Fat group (28.5 mg/dl). 
Both creatinine and urea parameters are associated with the renal function, so they were measure to 
determine if the kidney function was normal. Creatinine levels are similar in every group (p>0.05) and 
are below the reference values, as stated before. Urea reference values are 50.81± 0.35 mg/dl, so the 
results in this study are below the reference values. Hence, diet seems diet seems to have no impact 
kidney function. 
AST reference values are 42.9 ± 10.1 U/l. In this study the values for AST are all statistically 
different among the groups (p=0.001) and highly above the reference, with Schyzo group being the 
highest, reaching 184 U/l, and Fish Oil being the lowest, with 81 U/l.  
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Nanno group values for ALT are the lowest and different from the other three groups (36.4 U/l; 
p=0.001) but all the values are in accordance with the reference given (35.1 ± 13.3 U/l). 
Diet seems to have no effect on ALP levels, since they are statistically different in every group 
(Milk Fat=94.6 U/l; Fish Oil=129.9 U/l; Nanno=85.9 U/l; Schyzo=78.8 U/l; p=0.001) and are in 
accordance with the reference values (133 U/l). 
The levels of γ-GT are similar between Milk Fat and Fish Oil group (2.10 U/l and 2.19 U/l 
respectively; p>0.05) and are higher than Schyzo (1.10 U/l) and Nanno (0.44 U/l) groups. No 
reference values from Kaneko et al. (2008) were given for γ-GT. 
The total protein level and the hepatic biomarkers (AST, ALT, ALP and γ-GT) were measured to 
determine if algae-rich diets (of Nanno and Schyzo groups) could be toxic and affected the hepatic 
function in rats. Since only AST levels differ from the reference values, it can be assumed that diets 
did not affect normal hepatic function in this study. 
 
 
3.4.  Fatty acid profile in faeces 
Table 3.4 presents the fatty acid profile of the animals’ faeces in each group, showing differences 
in almost every fatty acid (p<0.05). Finding fatty acids in faeces means that the body did not retain 
those fatty acids, instead they were expelled as they were not fully needed in the amount given or not 
properly absorbed by the organism.  
Total FAME levels are higher in Fish Oil (126 mg/g) group and lower in Nanno group (64.2 mg/g), 
which means Nanno group had a higher absorption of fatty acid in the organism. Nannochloropsis, the 
algae used in Nanno group diet, was reported to be efficiently incorporated into the blood, liver, and 
brain lipids of rats (Werman et al., 2003) so reduced levels of total FAME in faeces for this group are 
in accordance with the expected. 
EPA (C20:5 n3) percentage is statistical different in Fish oil group compared to Nanno group 
(p<0.01), being higher in Nanno (5.45%) and residual in Fish oil (0.08%). Having more EPA on diet is 
concordant with having more EPA in faeces, as it happened in this study. Milk fat or Schyzo groups 
do not have EPA in faeces, since the diets of these groups also do not have EPA added. DHA (C22:6 
n3) was not detected in the faeces of any group, which was expected since DHA is highly retain by the 
body (Wurtman, 2014; Bradbury, 2011). 
Figure 3.2 shows the differences between the levels of n-3 and n-6 in the faeces of all groups. 
Omega-3 is higher in Nanno group and the levels are statistically different from the other three 
groups (6.20%; p=0.001). It was expected the levels of n-3 were higher in Schyzo group, since the diet 
of this group had a higher percentage of total n-3. This can be explained as the levels of n-3 given to 
Schyzo group were only in DHA form, not ALA form, and DHA is not readily released by the body 
(Bradbury, 2011). Omega-6 is also higher in Nanno group (4.05%) and lower in Fish Oil group 
(1.59%). The higher percentage on n-6 in Nanno group faeces can indicate a poor absorption of n-6 by 
Nanno group animals’ organism, but can be also due the higher amount of AA given in diet (5% 
compared with 0.3% given to Fish Oil group). 
The levels of saturated fatty acid (SFA), monounsaturated fatty acid (MUFA), polyunsaturated 
fatty acid (PUFA) are different in all groups (p=0.001), as shown in Figure 3.3. 
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Table 3.4 Fatty acid composition (% of total FA) and total FAME (mg/g) in faeces 
Milk Fat Fish Oil Nanno Schyzo 
 
Mean SD Mean SD Mean SD Mean SD Significance 
Total FAME 
(mg/g) 
C11:0 
111 ab 
0.30 b 
48.6 
0.180 
126 a 
0.54 a 
27.5 
0.122 
64.2 b 
0.75 a 
11.4 
0.208 
108 a 
0.33 b 
31.3 
0.050 
0.001 
0.001 
C12:0 . . . . 0.268 0.082 . . . 
C13:0 0.15 b 0.173 0.05 b 0.004 0.67 a 0.118 0.06 b 0.014 0.001 
C14:0 isobr 0.06 b 0.016 0.05 b 0.009 0.32 a 0.072 0.04 b 0.010 0.001 
C14:0 3.93 b 1.392 6.05 a 0.784 5.95 a 1.022 4.80 b 0.570 0.001 
C15:0 isobr 0.26 b 0.103 0.26 b 0.072 1.17 a 0.127 0.25 b 0.030 0.001 
C15:0 anteiso 0.406 0.153 0.370 0.091 0.462 0.086 0.455 0.075 0.161 
C15:0 1.35 bc 0.255 1.56 b 0.251 1.17 c 0.244 3.71 a 0.317 0.001 
C16:0 anteiso 0.14 bc 0.052 0.10 c 0.026 0.45 a 0.219 0.15 b 0.023 0.001 
C16:0 44.2 b 4.627 46.7 b 1.494 38.7 c 2.274 51.7 a 2.280 0.001 
C16:1 n9n7 0.09 d 0.036 0.33 b 0.081 7.20 a 1.181 0.17 c 0.043 0.001 
C17:0 isobr 0.282 0.030 0.293 0.108 0.265 0.011 0.258 0.014 0.198 
C17:0 0.79 b 0.055 0.82 b 0.039 0.64 c 0.048 1.61 a 0.045 0.001 
C16:3 n4 . . . . 0.141 0.026 . . . 
C17:1 0.20 bc 0.047 0.22 b 0.042 0.42 a 0.050 0.15 c 0.040 0.001 
C16:3 n3 0.066 0.016 . . 0.084 0.020 0.082 0.021 0.223 
C16:4 n3 0.067 0.025 0.062 0.010 0.058 0.026 . . 0.847 
C18:0 29.0 a 4.242 24.5 b 1.778 15.6 d 1.636 21.5 c 1.498 0.001 
C18:1 n9 4.89 a 1.225 4.55 a 0.701 4.80 a 0.738 3.78 b 0.385 0.002 
C18:1 n7 3.48 a 0.947 2.86 a 0.660 1.24 b 0.463 2.60 a 0.663 0.001 
C18:1 n5 1.20 a 0.388 1.05 a 0.197 0.63 b 0.052 1.20 a 0.350 0.001 
C19:0 isobr 0.41 a 0.126 0.24 b 0.048 0.14 c 0.018 0.21 b 0.052 0.001 
C18:2 n6 1.93 b 0.944 1.33 b 0.169 3.16 a 0.575 1.67 b 0.220 0.001 
C18:3 n6 0.128 0.094 . . . . . . . 
C19:0 0.14 b 0.036 0.13 b 0.010 0.18 a 0.014 0.18 a 0.011 0.001 
C18:3 n3 0.21 a 0.066 0.07 c 0.021 0.24 a 0.059 0.12 b 0.043 0.001 
C18:4 n3 0.161 0.101 0.172 0.091 0.115 0.095 0.136 0.054 0.620 
C20:0 1.41 a 0.440 1.13 a 0.264 0.79 b 0.112 0.71 b 0.109 0.001 
C20:1 n9 . . 1.172 0.179 . . . . . 
C20:1 n7 0.30 ab 0.264 0.43 a 0.105 0.11 b 0.073 0.25 b 0.138 0.001 
C20:2 n6 
C20:4 n6 
0.21 ab 
0.11 bc 
0.103 
0.073 
0.24 a 
0.07 c 
0.038 
0.024 
0.11 b 
0.82 a 
0.063 
0.161 
0.32 a 
0.19 b 
0.110 
0.060 
0.001 
0.001 
C20:3 n3 . . . . 0.233 0.085 . . . 
C20:5 n3 . . 0.08 b 0.023 5.45 a 1.242 . . 0.001 
C22:0 0.87 a 0.323 0.64 a 0.137 0.30 b 0.095 0.40 b 0.076 0.001 
C22:1 n11 . . 0.790 0.205 . . . . . 
C22:1 n9 . . 0.117 0.050 . . . . . 
C21:5 n3 0.195 0.075 0.095 0.082 . . . . 0.122 
C22:5 n3 0.57 a 0.310 0.37 ab 0.138 0.27 b 0.028 0.51 ab 0.229 0.014 
Total SFA 
Total MUFA 
Total PUFA 
Total n3 
Total n6 
n3/n6 
Total fatty acids 
Other fatty acids 
83.5 ab 
10.1 bc 
3.37 b 
1.11 b 
2.26 bc 
0.90 ab 
97.0 a 
2.99 b 
3.718 
2.323 
1.226 
0.440 
1.110 
1.428 
0.764 
0.764 
83.4 b 
11.5 b 
2.26 b 
0.63 b 
1.59 c 
0.41 b 
97.2 a 
2.84 b 
2.216 
1.767 
0.357 
0.292 
0.202 
0.213 
0.539 
0.539 
67.8 c 
14.4 a 
10.4 a 
6.20 a 
4.05 a 
1.52 a 
92.5 b 
7.45 a 
3.907 
1.849 
2.096 
1.410 
0.730 
0.156 
0.850 
0.850 
86.2 a 
8.14 c 
2.72 b 
0.56 b 
2.17b 
0.26 b 
97.1 a 
2.90 b 
2.026 
0.820 
0.486 
0.354 
0.278 
0.156 
1.159 
1.159 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
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Figure 3.2 Fatty acid profile of faeces (%) comparing n-3 and n-6 in the four experimental groups. 
 
 
Figure 3.3 Fatty acid profile of faeces (%), comparing SFA, MUFA and PUFA in the four experimental groups. 
 
The levels of SFA in faeces are lower for Nanno group (67.8%) compared to the other three 
groups, Schyzo group having the highest value (86.2%). Total SFA percentage in diets was almost the 
same in every group, so it was not expected to found different results in faeces. On the contrary, 
MUFA percentage is higher in Nanno group (14.4%) and lower in Schyzo group (8.14%). In the diets, 
MUFA has a higher percentage in Fish Oil group (26.6%) and lower in Schyzo group (20.4%).PUFA 
percentage is also higher in Nanno group (10.4%) and lower in Fish Oil group (2.26%). In diet, Milk 
Fat group has the highest percentage of PUFA (24.3%) and Fish oil group has the lowest (17.8%). 
Analysing Figure 3.3, it can be observed higher values of SFA and lower of MUFA and PUFA in 
rats’ faeces, which was expected since the diet composition fed to the rats of every group had also a 
higher percentage of SFA than MUFA and PUFA. Since the fatty acid metabolism of rats is similar to 
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humans, they cannot synthesize PUFA de novo (Crupi et al., 2013). Therefore, rats’ body would need 
to retain a higher percentage of PUFA and MUFA and lower of SFA, hence expel more of these fatty 
acids through faeces. 
The fatty acid profile can also be represented as a function of total FAME levels, multiplying the 
percentage of each fatty acid to the respective FAME level. In this case, Fish Oil has the highest 
values of SFA (105 mg/g) and Nanno group maintain the lowest (43.53 mg/g). Fish Oil group also 
presents higher values regarding MUFA (14.49 mg/g), which stay lower in Schyzo group (8.79 mg/g). 
PUFA levels continue to be higher in Nanno (6.68 mg/g) and lower in Fish Oil group (2.85 mg/g). The 
n-3 and n-6 fatty acids maintain the same profile as expressed in percentage, with Nanno having the 
highest global levels (3.98 mg/g and 2.6 mg/g for n-3 and n-6, respectively), Schyzo having the lowest 
levels for n-3 (0.6 mg/g) and Fish Oil presenting lower levels of n-6 (2 mg/g). 
Despite the small differences between percentage and mg/g values within the groups, the overall 
profile in faeces remains the same, presenting higher levels of SFA and lowers of PUFA (and by 
extends n-3 and n-6).  
 
 
3.5.  Fatty acid profile in erythrocytes 
In Table 3.5 are expressed the levels of fatty acid (%) and total FAME (mg/g) found in 
erythrocytes, which also show differences in almost every fatty acid (p<0.05). Total FAME, however, 
was not statistically different between the groups (p=0.521). Saturated fatty acid also did not show 
statistical differences in the four groups (p=0.221). Differences between the groups regarding SFA, 
MUFA, PUFA, n-3 and n-6 levels are presented in Figure 3.4. 
The percentage of EPA (C20:5 n3) is different in Fish Oil (3.08%) and Nanno (2.33%) groups 
(p=0.001) and is statistically similar in Milk Fat and Schyzo group (p>0.05), although found in 
residual levels (less than 1%). It was expected for EPA levels to be higher in Nanno group, since this 
group diet had a higher percentage of EPA compared to Fish oil group. This means that EPA was 
absorbed by the body, but was not metabolized and incorporated into the organs. DHA (C22:6 n3) 
levels are different in all groups (p=0.001), presenting higher values in Schyzo group (5.78%) and 
lower in Nanno group (0.68%), which was expected since Nanno diet has not DHA added. The 
residual levels found might be due to the conversion of DHA from the n-3 precursor (ALA) or by EPA 
in Nanno group. The same conversion might also have happened with Milk fat group, since DHA is 
found in this group’ erythrocytes (1.22%). 
PUFA levels are higher in erythrocytes than MUFA, which was expected since PUFA percentage 
was lower in faeces, indicating a better absorption of these fatty acids by the organism. Within the 
PUFA, omega-6 presents the highest percentage in the erythrocytes, compared to omega-3, which was 
also expected since all diets had a higher percentage of n-6 than n-3. 
Fatty acid in red blood cells, specifically EPA+DHA, are considered as a risk factor for coronary 
heart diseases and, therefore, the omega-3 index in erythrocytes is used as a systemic indicator of 
general health (Harris and Von Schacky, 2004). In this case, Fish Oil group presents the highest 
percentage of total n-3 and EPA and also presents a high percentage of DHA in red blood cells, which 
might indicate that fish oil is a good diet source for a better systemic incorporation of these fatty acids 
in the organism. 
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Table 3.5 Fatty acid composition (% of total FA) and total FAME (mg/g) in erythrocytes 
Milk Fat Fish Oil Nanno Schyzo 
 
Mean SD Mean SD Mean SD Mean SD Significance 
Total FAME (mg/g) 
C14:0 isobr 
9.8 
0.06 
2.03 
0.032 
10.6 
0.09 
1.11 
0.046 
10.8 
0.08 
0.905 
0.032 
11.7 
0.10 
2.52 
0.053 
0.521 
0.110 
C14:0 0.55 b 0.147 0.68 ab 0.126 0.73 a 0.105 0.78 ab 0.481 0.068 
C15:0 isobr 0.03 0.005 0.04 0.008 0.03 0.005 0.03 0.006 0.146 
C15:0 anteiso 0.07 b 0.015 0.073 b 0.024 0.08 b 0.008 0.11 a 0.018 0.001 
C15:0 0.36 c 0.068 0.43 bc 0.075 0.45 b 0.032 0.94 a 0.187 0.001 
C16:0 anteiso 2.343 0.199 2.312 0.176 2.610 0.265 2.240 0.314 0.049 
C16:0 23.9 3.335 25.7 3.090 26.0 1.297 24.8 2.665 0.329 
C16:1 n9 0.12 b 0.049 0.19 a 0.021 0.16 b 0.015 0.16 ab 0.035 0.005 
C16:1 n7 0.32 c 0.094 0.52 ab 0.099 0.72 a 0.193 0.42 bc 0.112 0.001 
C17:0 isobr 0.26 c 0.016 0.27 c 0.019 0.30 b 0.012 0.33 a 0.015 0.001 
C16:2 n4 0.06 0.025 0.07 0.078 0.08 0.033 0.06 0.017 0.437 
C17:0 0.46 c 0.028 0.44 c 0.027 0.58 b 0.020 0.76 a 0.025 0.001 
C16:3 n4 0.30 b 0.061 0.32 ab 0.082 0.35 ab 0.084 0.39 a 0.045 0.009 
C17:1 0.23 a 0.034 0.21 a 0.034 0.19 a 0.042 0.15 b 0.022 0.001 
C16:3 n3 2.44 0.185 2.42 0.218 2.50 0.185 2.64 0.458 0.609 
C16:4 n3 1.27 a 0.096 1.16 ab 0.109 1.08 b 0.098 0.89 c 0.120 0.001 
C18:0 13.8 a 0.391 13.1 b 0.576 13.5 ab 0.603 12.9 b 0.645 0.004 
C18:1 n9 7.84 b 0.205 8.50 a 0.163 8.00 ab 0.728 8.04 ab 0.796 0.001 
C18:1 n7 2.24 a 0.188 2.29 a 0.144 2.21 a 0.136 1.92 b 0.133 0.001 
C18:1 n5 0.40 b 0.024 0.40 b 0.024 0.43 a 0.014 0.36 c 0.025 0.001 
C19:0 isobr 0.04 0.004 0.04 0.010 0.05 0.014 0.04 0.005 0.100 
C18:2 n6 13.2 a 0.369 11.6 b 0.553 11.1 b 0.485 11.2 b 1.199 0.001 
C18:3 n6 0.04 b 0.003 0.05 a 0.008 . . . . 0.013 
C19:0 0.09 a 0.026 0.07 b 0.004 0.08 a 0.005 0.08 a 0.013 0.001 
C18:3 n4 0.02 b 0.004 . . 0.10 a 0.034 0.15 a 0.085 0.001 
C18:3 n3 0.14 a 0.054 0.09 b 0.013 0.06 c 0.015 0.07 bc 0.031 0.001 
C18:4 n3 0.05 0.022 0.05 0.028 0.05 0.007 0.06 0.023 0.660 
C20:0 0.11 ab 0.016 0.09 b 0.016 0.10 ab 0.013 0.13 a 0.036 0.047 
C20:1 n9 0.08 b 0.014 0.40 a 0.123 0.07 b 0.024 0.09 b 0.035 0.001 
C20:1 n7 0.08 0.017 0.09 0.019 0.09 0.024 0.09 0.011 0.339 
C20:2 n6 0.37 a 0.066 0.20 b 0.062 0.17 b 0.025 0.19 b 0.046 0.001 
C20:4 n6 20.5 a 1.745 14.6 c 1.613 17.7 b 0.485 17.9 b 2.050 0.001 
C20:3 n3 0.05 0.028 . . 0.03 0.005 . . 0.371 
C20:4 n3 0.41 ab 0.668 0.08 b 0.035 0.06 b 0.006 0.49 a 0.190 0.001 
C20:5 n3 0.26 c 0.068 3.08 a 0.321 2.33 b 0.153 0.47 c 0.238 0.001 
C22:0 0.29 b 0.064 0.27 b 0.090 0.28 b 0.025 0.39 a 0.038 0.002 
C22:1 n11 0.04 b 0.013 0.16 a 0.027 . . . . 0.001 
C22:1 n9 . . 0.043 0.011 . . . . . 
C21:5 n3 0.054 0.016 0.041 0.010 . . 0.067 0.000 . 
C22:4 n6 1.51 a 0.335 0.25 d 0.064 0.55 b 0.060 0.39 c 0.090 0.001 
C22:5 n6 0.34 b 0.059 0.10 d 0.020 0.14 c 0.022 1.75 a 0.223 0.001 
C22:5 n3 1.94 bc 1.204 2.55 b 0.500 3.50 a 0.267 0.95 c 0.270 0.001 
C24:0 0.890 0.253 0.827 0.217 0.849 0.108 0.932 0.221 0.747 
C22:6 n3 1.22 c 0.275 4.24 b 0.998 0.68 d 0.173 5.78 a 0.969 0.001 
C24:1 n9 0.452 0.129 0.570 0.186 0.400 0.091 . . 0.106 
SFA 43.188 3.290 44.403 2.900 45.770 1.826 44.265 2.535 0.221 
MUFA 11.8 b 0.336 13.3 a 0.419 12.3 ab 1.120 11.2 b 0.938 0.001 
PUFA 43.8 a 3.225 40.8 ab 3.139 40.5 b 0.816 43.3 a 2.830 0.008 
n3 7.5 c 1.982 13.7 a 1.955 10.3 b 0.438 11.2 b 1.572 0.001 
n6 35.9 a 1.865 26.7 d 1.293 29.7 c 0.471 31.5 b 1.629 0.001 
n3/n6 0.21 c 0.051 0.51 a 0.051 0.35 b 0.012 0.36 b 0.042 0.001 
Total 98.8 a 0.083 98.5 b 0.226 98.5 b 0.073 98.8 a 0.162 0.001 
Others 1.21 b 0.083 1.51 a 0.226 1.47 a 0.073 1.19 b 0.162 0.001 
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Figure 3.4 Fatty acid profile of erythrocytes (%), comparing the levels of SFA, MUFA, PUFA, n-3 and n-6 in the 
four experimental groups. 
 
 
3.6.  Fatty acid profile in brain 
Table 3.6 shows the fatty acid profile (%) and total FAME (mg/g) in the brain, with statistical 
differences only in some of the fatty acid. Total FAME levels are not statistical different between the 
groups (p=0.354), neither SFA (p=0.634), MUFA (p=0.886), PUFA (p=0.787) and n3 (p=0.084) 
percentage. 
DHA levels also did not present differences between the groups (p=0.084). This result can be 
explained knowing that DHA is the most preserved fatty acid in brain and its present in the brain cell 
membranes since their formation (Bradbury, 2011). Also, DHA is rapidly absorbed and retained by the 
brain, even when present in small amounts in plasma cells (Wurtman, 2014). The DHA found in the 
brain of every group might have been incorporated prior to the administration of DHA through the diet 
and, therefore, the groups did not present a significant difference of DHA percentage among each 
others. 
EPA was not detected in the brain of Milk Fat group, which was expected since this groups’ diet 
did not had any EPA added. Fish Oil has the highest percentage of EPA (0.07%), followed by Nanno 
group (0.04%) and Schyzo group (0.02%), being all statistically different (p=0.001). This is in 
accordance with the levels of EPA found in erythrocytes and faeces, where Fish Oil group presented 
the highest and lower percentage of EPA, respectively. However, EPA percentage was higher in 
Nanno group diet and was expected for this group to incorporate higher levels of EPA in the brain. 
The presence of EPA in Schyzo group can be due to a process of metabolic retroconversion of DHA in 
EPA, as found in other studies (Astarita et al., 2014). 
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Table 3.6 Fatty acid composition (% of total FA) and total FAME (mg/g) in brain 
Milk Fat Fish Oil Nanno Schyzo 
 
Mean SD Mean SD Mean SD Mean  SD Significance 
Total FAME 
(mg/g) 
C14:0 
153 
0.17 
22.7 
0.029 
175 
0.16 
34.2 
0.060 
169 
0.15 
19.8 
0.046 
157 
0.14  
13.3 
0.038 
0.354 
0.365 
C15:0 0.08 ab 0.014 0.07 b 0.025 0.07 b 0.024 0.11 a 0.026 0.021 
C16:0 anteiso 2.23 0.287 2.14 0.251 2.36 0.508 2.13  0.255 0.641 
C16:0 18.92 2.317 18.6 4.025 18.9 3.568 17.6  2.440 0.692 
C16:1 n9 0.11 0.017 0.12 0.024 0.11 0.021 0.09  0.031 0.293 
C16:1 n7 0.38 0.053 0.44 0.110 0.41 0.070 0.38  0.058 0.406 
C17:0 isobr 0.11 ab 0.028 0.11 b 0.016 0.13 ab 0.029 0.14 a  0.018 0.008 
C17:0 0.17 b 0.015 0.16 b 0.013 0.19 ab 0.026 0.23 a  0.039 0.001 
C16:3 n4 0.24 0.063 0.28 0.071 0.22 0.078 0.25  0.095 0.348 
C17:1 0.07 0.017 0.08 0.019 0.06 0.014 0.06  0.017 0.366 
C16:3 n3 3.90 0.157 4.10 0.242 4.36 0.732 4.03  0.161 0.095 
C16:4n-3 1.45 0.336 1.40 0.188 1.44 0.161 1.42  0.244 0.963 
C18:0 19.0 1.080 19.6 0.513 19.9 0.939 19.2  0.799 0.174 
C18:1 n9 15.8 1.208 16.6 0.785 15.9 0.697 16.1  1.366 0.238 
C18:1 n7 3.03 0.269 2.93 0.115 3.01 0.087 2.88  0.241 0.239 
C18:1 n5 . . 0.03 a 0.002 0.03 a 0.003 0.02 b  0.003 0.011 
C18:2 n6 1.04 a 0.181 0.92ab 0.106 0.81 b 0.081 0.83 ab  0.232 0.011 
C19:0 0.05 0.009 0.05 0.005 0.05 0.010 0.05  0.005 0.420 
C18:3 n4 0.00 0.000 0.02 0.008 0.02 0.003 0.02  0.005 0.630 
C18:4 n3 0.05 0.007 0.05 0.018 0.06 0.014 0.05  0.006 0.569 
C20:0 0.46 0.196 0.44 0.101 0.44 0.098 0.44  0.108 0.994 
C20:1 n11 0.00 0.000 0.06 0.007 0.22 0.446 0.05  0.010 0.240 
C20:1 n9 1.44 0.809 1.33 0.406 1.36 0.272 1.44  0.486 0.962 
C20:1 n7 0.45 0.218 0.40 0.105 0.41 0.085 0.43  0.124 0.915 
C20:2 n6 0.15 0.050 0.11 0.020 0.12 0.016 0.10  0.022 0.050 
C20:4 n6 10.1 0.803 9.28 0.592 9.60 1.346 9.59  0.511 0.202 
C20:5 n3 . . 0.07 a 0.015 0.04 b 0.009 0.02 c  0.005 0.001 
C22:0 0.48 0.209 0.41 0.140 0.43 0.156 0.46  0.145 0.844 
C22:1 n11 0.22 0.110 0.18 0.059 0.20 0.046 0.20  0.082 0.810 
C22:1 n9 0.10 0.009 0.11 0.025 0.11 0.036 0.12  0.056 0.552 
C23:0 0.24 0.032 0.24 0.056 0.28 0.077 0.25  0.047 0.736 
C22:4 n6 3.21 a 0.408 2.52 b 0.525 2.98 ab 0.517 2.73 ab  0.462 0.031 
C22:5 n6 0.80 0.281 0.53 0.530 0.72 0.824 0.94  0.172 0.192 
C22:5 n3 0.28 ab 0.128 0.34 a 0.055 0.41 a 0.103 0.16 b  0.019 0.001 
C24:0 1.11 0.400 0.89 0.326 0.99 0.462 1.00  0.280 0.705 
C22:6 n3 11.4 1.701 13.0 2.001 10.9 2.423 13.1  2.047 0.084 
C24:1 n9 1.43 0.714 1.14 0.457 1.27 0.597 1.25  0.471 0.800 
SFA 42.9 2.522 42.8 3.970 43.8 3.948 41.6  2.854 0.634 
MUFA 22.9 3.038 23.3 1.542 22.8 0.879 22.9  2.302 0.886 
PUFA 32.3 2.463 32.6 3.073 31.5 3.801 33.2  2.903 0.787 
n3 16.9 1.515 19.0 2.363 17.1 2.309 18.7  1.971 0.084 
n6 15.3 a 1.234 13.3 b 0.960 14.12 ab 1.613 14.2 ab  0.940 0.018 
n3/n6 1.11 c 0.098 1.42 a 0.137 1.21 bc 0.102 1.32 ab  0.071 0.001 
Total 98.1 b 0.336 98.7a 0.236 98.0 b 0.448 97.7 b  0.470 0.001 
Others 1.87 a 0.336 1.33 b 0.236 1.99 a 0.448 2.27a  0.470 0.001 
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Representing the fatty acid profile in brain as a function of total FAME keeps the relative 
proportion of fatty acids as represented in percentage form, despite the lack of significant differences. 
SFA are found in a higher amount in brain (74 mg/g in Fish oil and Nanno groups and 65 mg/g in 
Milk Fat and Schyzo groups), compared to MUFA (37.54 mg/g average in all groups) and PUFA (57 
mg/g in Fish Oil group, 52.63 mg/g in Nanno and Schyz groups and 49.45 in Milk Fat group). Within 
the PUFA, Milk Fat group presents lower levels of n-3 (25.8 mg/g) compared to the other groups (30.5 
mg/g average), but all groups present the same amount of n-6 in the brain (23.21 mg/g average). EPA 
levels are still higher for Fish Oil group (0.12 mg/g) compared to Nanno and Schyzo groups (0.07 
mg/g and 0.03 mg/g, respectively). DHA is also present in higher amounts in the brain of Fish Oil 
group (22.81 mg/g), followed by Schyzo (20.59 mg/g), Nanno (18.35 mg/g) and Milk Fat groups 
(17.37 mg/g). 
Since Fish Oil group presents the highest values of EPA and DHA in the brain, compared to Nanno 
and Schyzo groups, it can be assumed that the combined intake of EPA+DHA promotes a better 
absorption of these fatty acids to the brain than the individual intake. The mechanism by which this 
incorporation happens should be better study in the future. 
 
 
3.7.  Serotonin and catecholamines in serum 
Table 3.7 show the catecholamines levels in serum, with statistical differences only in epinephrine 
and dopamine parameters (p=0.016 and p=0.047, respectively). 
Epinephrine levels are lower in Milk Fat group (1826 ng/l), despite being similar with Fish Oil and 
Nanno groups (3098 ng/l and 4117 ng/l, respectively; p>0.05), which are in turn similar with Schyzo 
group (4889 ng/l). 
Dopamine is higher in Fish Oil group (115 ng/l) but its value is similar with the ones found in Milk 
Fat and Schyzo groups (78.9 ng/l and 58.9 ng/l, respectively; p>0.05), which in turn are similar with 
the Nanno group (43.1 ng/l). 
 
Table 3.7 Serotonin, norepinephrine, epinephrine and dopamine levels in brain 
 
Milk Fat Fish Oil Nanno Schyzo 
 
 
Mean SD Mean SD Mean SD Mean SD Significance 
Serotonin (μg/L) 76.3 92.6 21.4 25.7 49.9 39.6 114 116 0.061 
Norepinephrine (ng/l) 1257 252 1377 363 1442 430 1806 486 0.082 
Epinephrine (ng/l) 1826 b 1138 3098 ab 1587 4117 ab 3667 4889 a 2392 0.016 
Dopamine (ng/l) 78.9 ab 52.1 115 a 62.2 43.1 b 27.8 58.9 ab 40.8 0.047 
 
 
Both EPA and DHA do not seem to affect epinephrine regulation, with DHA having a less 
predominant role. Epinephrine is a stress hormone (Giles et al., 2015) whose levels were reported to 
low with the administration of a fish oil diet in a stress response situation (Pusceddu et al., 2016; 
Heinrichs, 2010). In this work, Fish Oil group has lower levels of epinephrine than Nanno and Shcyzo 
groups, which is in accordance with the finding. However, Milk Fat group is the one with the lowest 
levels of plasma epinephrine and this groups’ diet does not have neither EPA nor DHA added. 
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Furthermore, its levels are similar with both Fish Oil and Nanno groups’, which can lead to the 
assumption that neither EPA nor DHA affect the epinephrine system, and can even worse it, 
contradicting the other studies results. 
In this study, dopamine was measured to determine the level of motivation of the animals, being 
higher values related to higher motivation. Various studies report the role of LC-PUFA on dopamine 
regulation, being lower levels of dopamine in the system related with PUFA deficiency (Husted and 
Bouzinova, 2016; Morgese and Trabace, 2016; Pusceddu et al., 2016). In this study, the lowest levels 
of dopamine in plasma are found in Nanno and Schyzo groups. Fish Oil group, however, presents the 
highest levels of dopamine, which is in accordance with the other results found. Therefore, it can be 
assumed that an EPA and DHA alone have a lower impact on regulating dopaminergic system than an 
EPA+DHA diet. 
 
 
3.8.  Integrative discussion 
Behavioural FST revealed the potential benefit effect of EPA+DHA intake, rather than individual 
fatty acid intake, since Fish Oil group presented a better overall performance. These results can be due 
to the highest levels of LC-PUFA found in erythrocytes and brain, which might indicate that fish oil is 
a good diet source for a better systemic incorporation of fatty acids in the organism. 
Both Milk Fat and Nanno presented the worse results in FST, with high immobile levels, low 
latency and higher frequencies. Schyzo group has more similar results to Fish Oil group than Nanno 
group, which might indicate a better role of individual DHA, contrarily to individual EPA. However, 
Milk Fat group results were often similar with the other groups. The presence of DHA in Milk Fat 
group’ brain, in similar levels as the other groups, can help explain these similar behavioural results. 
Nevertheless, DHA alone is not the key factor in positive behaviours, since Schyzo group performance 
is lower than the Fish Oil group.  
EPA lack-of-effect in Nanno group can also be explained, since the levels found in faeces are high 
and in brain they are lower than expected. This means EPA was not properly absorbed and 
metabolized, therefore, its action leads to lower overall effects and must be better clarified. A diet rich 
in Nannochloropsis oil instead of algae crude fibers, as it was administered in this work, can possible 
increase de bioavailability of EPA and increase the absorption by rats’ organism, which may influence 
the animals’ performance in all parameters measured. 
Regarding biochemical values in plasma, a diet rich in EPA+DHA form seems to lower total lipids 
levels better than individual intake of these fatty acids. However, EPA tends to present similar results 
as the EPA+DHA diet, contrary to a DHA diet, so the benefit effects may be due to EPA action. More 
studies need to be done in order to clarify this relation. Total cholesterol levels can also be lowered 
with an EPA+DHA diet, but individual intakes of these fatty acids are less effective. 
Dopamine and epinephrine levels were also better for Fish Oil group, reinforcing the behavioural 
results found and also the benefit power of fish oil diet. 
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Conclusion and future perspectives 
The underlying hypothesis of this work was that EPA and DHA would have different behavioural 
effects when ingested individually and in combined form. EPA diet alone had a better cardiovascular 
and health impact, but poor behavioural modulation. DHA diet alone presented better behavioural 
effects than EPA. Fish oil diet (rich in both fatty acids) revealed the best overall results regarding 
behaviour, plasma biomarkers and dopamine levels. Therefore, an EPA+DHA diet seems to be more 
adequate for the promotion of whole organism health and also helps increasing active behaviours, 
which can be benefit for neurologic conditions, as depression or other mood disorders. 
This work highlighted the role of EPA and DHA in active/passive behaviour and overall health in 
rats. However, there were some limitations that did not allow a better delve into this role and that can 
be improved in future studies. 
A better adjustment of the diets is needed, regarding the chemical composition and fatty acid 
quantities, in order to be the most similar as possible between the different groups, with only one 
variation (in this case the specific amount of EPA, DHA or EPA+DHA). Increasing the doses or the 
experimental time might help having clear results regarding individual role of the different fatty acids. 
Also, start feeding the animals with a specific diet early in their lives, instead of feeding a standard 
diet (which has all essential nutritional compounds), might help reducing the postnatal intake of EPA 
and DHA and, therefore, reduce the postnatal incorporation of undesirable fatty acids in specific 
groups. 
A way to access the specific effects of EPA and DHA, not included in this study, is through other 
mechanisms, as endocannabinoid system or analyzing other serum markers. Another way is to use 
different behavioural tests and cross the information obtained to corroborate the results or perform the 
test with recourse of inhibition/simulation drugs. The use of transgenic rats, made specific in 
accordance with the proposed objectives, might also help reducing confounding variablesrelated to 
internal variability, inherent to the animals themselves. 
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